---
http_interactions:
- request:
    method: get
    uri: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d
    body:
      encoding: US-ASCII
      string: ''
    headers: {}
  response:
    status:
      code: 200
      message: OK
    headers:
      Date:
      - Fri, 06 Sep 2013 19:30:47 GMT
      Server:
      - Apache
      Set-Cookie:
      - CFAUTHORIZATION_dailymed_48863B5BDCA01B090A4358859A61B7726=;expires=Thu, 06-Sep-2012
        19:30:48 GMT;path=/
      - CFAUTHORIZATION_dailymed_48863B5BDCA01B090A4358859A61B7726=;expires=Thu, 06-Sep-2012
        19:30:48 GMT;path=/
      - CFID=158434885;expires=Sun, 30-Aug-2043 19:30:48 GMT;path=/
      - CFID=158434888;expires=Sun, 30-Aug-2043 19:30:48 GMT;path=/
      - CFTOKEN=3bfce2608073fcd3-8F8C79BB-CC20-5A1C-0A885856FAFBE0D0;expires=Sun,
        30-Aug-2043 19:30:48 GMT;path=/
      - CFTOKEN=e9002635d3824921-8F8C7A4E-CC53-A461-A8A15D38B7F3246B;expires=Sun,
        30-Aug-2043 19:30:48 GMT;path=/
      - JSESSIONID=8430cd62e6b9c14fc252744f627516a51233;path=/
      Transfer-Encoding:
      - chunked
      Content-Type:
      - text/html; charset=UTF-8
      X-Vip-Info:
      - 130.14.16.124:80
      X-Pool-Info:
      - /Common/dailymed_p 10.1.11.29 80
    body:
      encoding: UTF-8
      string: "\r\n<!DOCTYPE html PUBLIC \"-//W3C//DTD XHTML 1.0 Transitional//EN\"
        \"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd\">\r\n<html xmlns=\"http://www.w3.org/1999/xhtml\"
        xml:lang=\"en\" lang=\"en\">\r\n<head>\r\n<meta http-equiv=\"Content-Type\"
        content=\"text/html; charset=utf-8\" />\r\n<meta http-equiv=\"X-UA-Compatible\"
        content=\"IE=edge\" />\r\n<link rel=\"shortcut icon\" href=\"/dailymed/images/favicon.ico\"
        />\r\n<meta name=\"ROBOTS\" content=\"NOFOLLOW\" />\r\n\r\n\r\n\r\n<script
        type=\"text/javascript\" src=\"/dailymed/scripts/1.3.2/jquery.js\"></script>
        \r\n<script type=\"text/javascript\" src=\"/dailymed/scripts/autocomplete/jquery.autocomplete.js\"></script>\r\n\r\n<link
        rel=\"stylesheet\"   href=\"/dailymed/styles/base.css\" type=\"text/css\"
        \ />\r\n\r\n<link rel=\"stylesheet\"   href=\"/dailymed/scripts/autocomplete/jquery.autocomplete.css\"
        type=\"text/css\" />\r\n\r\n<script src=\"/dailymed/scripts/drop_down.js\"
        type=\"text/javascript\"></script>\r\n<script src=\"/dailymed/scripts/shared.js\"
        type=\"text/javascript\"></script>\r\n<!--[if IE]>\r\n<link rel=\"stylesheet\"
        type=\"text/css\" href=\"/dailymed/styles/ie-hacks.css\" />\r\n<![endif]-->\r\n<script
        type=\"text/javascript\">\r\n\t$(document).ready(function(){\r\n\t\t\r\n\t\t//
        check to see if autocomplete plugin has been loaded by looking for existance
        of \"autocomplete\" function in jQuery object\r\n\t\tif( $.fn.autocomplete
        ) {  \r\n\t\t\t// THE PLUGIN HAS BEEN LOADED!\r\n\t\t\t//alert(\" autocomplete
        is already loaded! great! \");\r\n\r\n\t\t}\r\n\t\telse {\r\n\t\t\t// reinsert
        the script tag into the head to load the autocomplete plugin\r\n\t\t\t\r\n\t\t\t//alert(\"
        we need to load in autocomplete...\" );\r\n\t\t\t$(\"head\").append('<script
        type=\"text/javascript\" src=\"/dailymed/scripts/autocomplete/jquery.autocomplete.js\"
        />');\r\n\t\r\n\t\t}\r\n\t\t\r\n\t\t// actually activate autocomplete\r\n\t\t$(\"#startswith\").autocomplete(\"/dailymed/autocomplete.cfm?key=search\",{\r\n\t\t\twidth:
        275,\r\n\t\t\tselectFirst: false,\r\n\t\t\tcacheLength:1,\r\n\t\t\tmax:200,\r\n\t\t\tmatchSubset:false,\r\n\t\t\tdelay:300,\r\n\t\t\tminChars:3\r\n\t\t});\r\n\t});\r\n\t\r\n
        \   \r\n\r\n \r\n  </script>\r\n  \r\n<noscript>Your browser does not support
        JavaScript!</noscript>\r\n\r\n\r\n\r\n\t\t\r\n\r\n<title>LEXAPRO (ESCITALOPRAM
        OXALATE) TABLET [CARDINAL HEALTH]</title>\r\n<link rel=\"alternate\" type=\"application/rss+xml\"
        href=\"/dailymed/labelrss.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d\"\r\ntitle=\"RSS
        Feed for LEXAPRO (ESCITALOPRAM OXALATE) TABLET [CARDINAL HEALTH] Label\"/>\r\n<link
        rel=\"bookmark\" href=\"lookup.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d\"
        title=\"LEXAPRO (ESCITALOPRAM OXALATE) TABLET [CARDINAL HEALTH]\" />\r\n<link
        rel=\"stylesheet\" type=\"text/css\" href=\"fdastyles/spl.css\" />\r\n\r\n<link
        rel=\"stylesheet\" type=\"text/css\" href=\"styles/layouts/slidingdoors.css\"
        />\r\n\r\n</head>\r\n<body>\r\n\r\n\t<div id=\"controls\">\r\n<ul>\r\n    \r\n\t<li><a
        class=\"skipicon1\" href=\"#druglabelcontent\" title=\"Skip to DrugLabel content
        paragraph\">Skip to DrugLabel content</a></li>\r\n\t<li><a class=\"skipicon2\"
        href=\"#dmsections\" title=\"Skip to DrugLabel sections paragraph\">Skip to
        DrugLabel sections</a></li>\r\n  \r\n </ul>\r\n</div>\r\n  <div id=\"dailymedbanner\">\r\n
        \ \t\t<div id=\"brandimage\">\r\n        <img src=\"images/DM_LOGO_HEADER.png\"
        alt=\"DailyMed Logo Header image\" />\r\n        </div>\r\n        <div id=\"top\">\r\n
        \         <h1>Daily\r\n            <span>Med</span>\r\n          </h1>\r\n
        \         <h2>\r\n            <span>Current </span>\r\n            <span>Medication
        </span>\r\n            <span>Information</span>\r\n          </h2>\r\n        </div>\r\n
        \ </div>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<div id=\"actions\">\r\n\t<div
        id=\"options\">\r\n\t\t<h2>Options</h2>\r\n\t\t<ul id=\"dmnav\">\r\n\t      \t\t<li>\r\n\t\t\t\t\t<a
        \ttitle=\" Link to DailyMed Home \"\r\n\t\t\t\t\t\thref='/dailymed/about.cfm'\r\n\t\t\t\t\t\tid=\"home\">Home</a>\r\n\t\t\t\t</li>\r\n\t
        \     \t\t<li>\r\n\t\t\t\t\t<a \ttitle=\" Link to E-mail Label Information
        \"\r\n\t\t\t\t\t\thref=\"/dailymed/emailWebLink.cfm\"\r\n\t\t\t\t\t\tid=\"email\">E-mail
        Label Information</a>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li><a \tclass=\"rightarrow\"\r\n\t\t\t\t\t\thref=\"#\"\r\n\t\t\t\t\t\ttitle=\"Links
        to download options\">Downloads</a>\r\n\t\t\t\t\t<ul>\r\n\t\t\t\t\t\t<li>\r\n\t\t\t\t\t\t\t<a\ttitle=\"
        Link opens new window to download all drug labels \"\r\n\t\t\t\t\t\t\t\thref=\"/dailymed/downloadLabels.cfm\">Download
        All Drug Labels</a>\r\n\t\t\t\t\t\t</li>\r\n                        <li>\r\n
        \                       \t<a\ttitle=\" Link opens new window to download all
        indexing files\" \r\n                            \thref=\"/dailymed/downloadIndexing.cfm\">Download
        All Indexing Files</a>\r\n                        </li>\r\n                        <li>\r\n
        \                       \t<a\ttitle=\" Link opens new window to download all
        mapping files\" \r\n                            \thref=\"/dailymed/downloadMappingFiles.cfm\">Download
        All Mapping Files</a>\r\n                        </li>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<li>\r\n\t\t\t\t\t\t\t<a\ttitle=\"
        Link opens new window to download this label (XML) \"\r\n\t\t\t\t\t\t\t\thref=\"/dailymed/getFile.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d&amp;type=zip&amp;name=LEXAPRO\">Download
        this Label(XML)</a>\r\n\t\t\t\t\t\t</li>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<li>\r\n\t\t\t\t\t\t\t<a\thref=\"http://www.fda.gov/oc/datacouncil/spl.html\"\r\n\t\t\t\t\t\t\t\ttitle=\"Link
        opens in a new window for FDA SPL Resources\"\r\n\t\t\t\t\t\t\t\ttarget=\"FDA\">FDA
        SPL XML Schema</a>\r\n\t\t\t\t\t\t</li>\r\n\t\t\t\t\t\t<li>\r\n\t\t\t\t\t\t\t<a\thref=\"ftp://public.nlm.nih.gov/nlmdata/.dailymed/SPLIMAGE_Specification_v3_0_2_2012_03212012_FINAL_c_Figures.pdf\"\r\n\t\t\t\t\t\t\t\ttitle=\"Link
        opens in a new window to download SPLIMAGE Specification Version 3.0.2\"\r\n\t\t\t\t\t\t\t\ttarget=\"ftpsplimagespecs\">SPLIMAGE
        Specification Version 3.0.2</a>\r\n\t\t\t\t\t\t</li>\r\n                        \r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</ul>\r\n\t\t\t\t</li>\r\n\t\t\t\t\r\n\r\n\t\t\t\t<li><a
        \ttitle=\"SPL History\"\r\n\t\t\t\t\t\thref=\"/dailymed/splshistory.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d\"\r\n\t\t\t\t\t\tid=\"splhistory\">SPL
        History </a>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li><a \ttitle=\"Link to Print this
        Label\"\r\n\t\t\t\t\t\thref=\"/dailymed/fda/fdaDrugXsl.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d&amp;type=display\"\r\n\t\t\t\t\t\tid=\"printitem\"\r\n\t\t\t\t\t\ttarget=\"_blank\">
        Print this Label </a>\r\n\t\t\t\t</li>\r\n                <li>\r\n                \r\n\t\t\t\t\r\n
        \                   <a\ttitle=\"Download PDF of this Label\" \r\n                            href=\"/dailymed/getFile.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d&amp;type=pdf&amp;name=b49f45d7-432f-4529-b382-3a65f7643e2d\"\r\n
        \                           id=\"downloadpdf\"> Download this Label (PDF)</a>\r\n
        \                 \r\n                             \r\n                </li>
        \       \r\n\t\t\t\t\r\n\t      \t    <li>\r\n\t\t\t\t\t\t<a\ttitle=\" Notify
        of Updates \"\r\n\t\t\t\t\t\thref=\"/dailymed/rsshome.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d\"\r\n\t\t\t\t\t\tid=\"rss\">Notify
        of Updates</a>\r\n\t\t\t\t</li>\r\n\t      \t\t<li>\r\n\t\t\t\t\t<a\ttitle=\"
        Contact Us \"\r\n\t\t\t\t\t\thref=\"/dailymed/contactUs.cfm\"\r\n\t\t\t\t\t\tid=\"contact\">Contact
        Us</a>\r\n\t\t\t\t</li>\r\n                <li>\r\n\t\t\t\t\t<a\ttitle=\"
        Help \"\r\n\t\t\t\t\t\thref=\"/dailymed/help.cfm\"\r\n\t\t\t\t\t\tid=\"help\">Help</a>\r\n\t\t\t\t</li>\r\n
        \               <li>\r\n\t\t\t\t\t<a\ttitle=\" Web Services \"\r\n\t\t\t\t\t\thref=\"/dailymed/help.cfm#webservices\"\r\n\t\t\t\t\t\tid=\"help\">Web
        Services</a>\r\n\t\t\t\t</li>\r\n                <li class=\"new-option\">\r\n
        \               \t<a\ttitle=\" Browse Drug Classes \"\r\n                    \thref=\"/dailymed/browseClasses.cfm\"\r\n
        \                       id=\"browse\">Browse Drug Classes<img src=\"/dailymed/images/new.gif\"
        alt=\"New menu option\" style=\"border:none;\"/>\r\n                    </a>\r\n
        \                   \r\n                </li>\r\n\t\t\t\t<li><h2>Additional
        Resources</h2></li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<a\tid=\"splimagesspec\"\r\n\t\t\t\t\t\thref=\"splimagesspec.cfm\"\r\n\t\t\t\t\t\ttarget=\"SPLIMAGESPEC\"\r\n\t\t\t\t\t\ttitle=\"SPLIMAGE
        Specifications\">SPLIMAGE Specification Version 3.0.2  </a>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<a\tid=\"report\"\r\n\t\t\t\t\t\thref=\"http://www.fda.gov/medwatch/how.htm\"\r\n\t\t\t\t\t\ttarget=\"FDA\"\r\n\t\t\t\t\t\ttitle=\"FDA
        Page to Report Adverse Event\">Report Adverse Event</a>\r\n\t\t\t\t</li>\r\n\t\t\t\t\r\n\t\t\t\t\r\n\t\t\t\r\n\t\t\t\r\n\r\n\t\t\t\r\n\t\t\t
        \   <li><a href=\"http://www.nlm.nih.gov/search/medlineplus?query=ESCITALOPRAM\"
        title=\"Link opens new window to MedlinePlus Information\" target=\"medlinePlus\">MedlinePlus
        Information</a></li>\r\n\t\t\t    <li><a href=\"http://www.clinicaltrials.gov/ct/search?submit=Search&amp;term=ESCITALOPRAM\"
        title=\"Link opens new window to Find Clinical Trials\" target=\"clinicalTrials\">Find
        Clinical Trials</a></li>\r\n\t\t\t\t<li><a href=\"http://www.drugbank.ca/search/search?query=APRD00683\"
        title=\"Link opens new window to University of Alberta DrugBank\" target=\"drugBank\">Biochemical
        Data Summary</a></li>\r\n\t\t\t    <li><a href=\"#\" class=\"rightarrow\"
        title=\"Links to Search PubMed Articles\">Search PubMed Articles</a>\r\n\t\t\t\t
        \ <ul>\r\n\t\t\t\t\t<li><a href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESCITALOPRAM[All
        Fields]\" title=\"Link opens new window for All Citations\" target=\"pubmed\">All
        Citations</a></li>\r\n\t\t\t\t\t<li><a href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESCITALOPRAM/AE\"
        title=\"Link opens new window for Adverse Effects\" target=\"pubmed\">Adverse
        Effects</a></li>\r\n\t\t\t\t\t<li><a href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESCITALOPRAM/TU\"
        \ title=\"Link opens new window for Therapeutic Use\" target=\"pubmed\">Therapeutic
        Use</a></li>\r\n\t\t\t\t\t<li><a href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESCITALOPRAM/PD\"
        title=\"Link opens new window for Pharmacology\" target=\"pubmed\">Pharmacology</a></li>\r\n\t\t\t\t\t<li><a
        href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESCITALOPRAM[All
        Fields] AND Clinical Trial[ptyp]\" title=\"Link opens new window for Clinical
        Trials\" target=\"pubmed\">Clinical Trials</a></li>\r\n\t\t\t\t  </ul>\r\n\t\t\t
        \   </li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<a href=\"http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+lact:@na+ESCITALOPRAM\"
        target=\"toxnet\" title=\"Link opens new window for Presence in Breast Milk\">Presence
        in Breast Milk</a>\r\n\t\t\t\t\r\n\t\t\t\t</li>\r\n\r\n\t     </ul>\r\n\t\t
        \r\n\t\t \t<div id=\"mdswitch\">\r\n\t\t\t\t\r\n\t\t\t\t\t<a  href=\"/dailymed/drugInfo.cfm?id=104317&amp;dictionary=on\"\r\n\t\t\t\t\t\ttitle=\"Turn
        Dictionary Words On\">\r\n\t\t\t\t\t\t<img src=\"/dailymed/images/dictionaryon.jpg\"
        alt=\"Turn Dictionary Words On\"/>\r\n\t\t\t\t\t</a>\r\n\t\t\t\t\r\n\t\t\t</div>\r\n\t\t\r\n\r\n\t</div>\r\n\t\t\r\n\t\t\r\n\t\t\t\r\n\r\n<link
        rel=\"stylesheet\" href=\"styles/thickbox.css\" type=\"text/css\" media=\"screen\"
        />\r\n\r\n<script language=\"JavaScript\" src=\"scripts/1.3.2/jquery.js\"></script>
        \r\n<script language=\"javascript\" type=\"text/javascript\" src=\"scripts/thickbox.js\"></script>\r\n\r\n\r\n<script
        type=\"text/javascript\" src=\"scripts/autocomplete/lib/jquery.bgiframe.min.js\"></script>\r\n<script
        type=\"text/javascript\" src=\"scripts/autocomplete/lib/jquery.dimensions.js\"></script>\r\n\r\n<script
        language=\"JavaScript\"> \r\n\r\n/*$(function(){\r\n\t$(\"img[id='prdimg'][src*='.jpg']\").thumbPopup({\r\n\t\timgSmallFlag:
        \"_s\",\r\n\t\timgLargeFlag: \"_l\",\r\n\t\tcursorLeftOffset: 150\r\n\t});\r\n\t\r\n});*/\r\n</script>
        \r\n\r\n<style type=\"text/css\">\r\n\t\thtml body {\r\n\t\tmin-width:1024px;\r\n\t\t}\r\n
        \       .smallimage {\r\n            border: 1px solid ##ACBECE;\r\n        }\r\n</style>\r\n\r\n\r\n\r\n\r\n\t\r\n\t\r\n\r\n\t\r\n\t\r\n\r\n\t\r\n\t\r\n
        \   \r\n\t    \r\n\r\n\t\r\n\t\r\n\t\r\n\r\n\t\r\n\t\r\n\t\r\n\r\n\t\r\n\t\t\r\n\t\t\r\n\t\r\n\r\n\t\r\n\t\r\n\r\n\t\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\r\n\t\r\n\t\r\n\t\r\n\t\r\n\t\t\r\n\t\r\n\t\t\r\n\r\n\t\t\r\n\t\r\n\t\r\n\t\r\n\t\r\n\t\r\n\r\n\t\r\n\t\t\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n\r\n\t\r\n
        \   \r\n\t\r\n    \r\n    \r\n     \r\n    \r\n    \r\n    \r\n    \r\n\t\r\n\t
        \  \r\n    \r\n\t\r\n    \r\n    \r\n        \r\n    \r\n       \r\n    \r\n\r\n\r\n\r\n\r\n\r\n\t\t\r\n</div>\r\n\r\n\r\n\r\n\r\n\r\n\r\n<div
        id=\"content\">\r\n<div id=\"searchpane\">\r\n\r\n\r\n\r\n<div id=\"search\">\r\n<form
        action=\"/dailymed/search.cfm\" name=\"searchform\">\r\n<div class=\"divtable\">\r\n
        \   <div class=\"divtr\">\r\n            <div class=\"divtd\">Search :</div>\r\n
        \           <div class=\"divtd\">\r\n            \t<label for=\"startswith\"
        class=\"invisibletag\">Enter a drug Name to search</label>\r\n                <input
        style=\"width:95%;\"\r\n                type=\"text\" \r\n                id=\"startswith\"
        \r\n                name=\"startswith\" \r\n                title=\"enter
        a drug name to search\"  \r\n                onclick=\"javascript:resetme()\"
        /> &nbsp;           \r\n            </div>\r\n            <div class=\"divtd\">\r\n
        \             \t<label for=\"go\" class=\"invisibletag\">Go</label>\r\n                <input
        type=\"image\" \r\n                src=\"/dailymed/images/goButton.gif\" \r\n
        \               alt=\"Click this button to start your drug name search\" \r\n
        \               title=\"Click this button to start your drug name search\"
        \r\n                id=\"go\"/> &nbsp;\r\n            </div>\r\n            <div
        class=\"divtd80\">\r\n            \t<a href=\"/dailymed/advancedSearch.cfm\">Advanced
        Search</a>\r\n            </div>\r\n    </div>\r\n    <div class=\"divtr\">\r\n
        \   \t\t<div class=\"divtd85\">Limits:</div>\r\n            <div class=\"divtd85\">\r\n
        \               <input  class=\"searchoptions\"  type=\"radio\" name=\"searchdb\"
        value=\"drugname\" id=\"name-radio\" title=\"Drug Name\" />\r\n                <label
        for=\"name-radio\" class=\"searchoptions\">Drug Name</label>\r\n                <input
        \ class=\"searchoptions\"  type=\"radio\" name=\"searchdb\" value=\"ndc\"
        id=\"ndc-radio\" title=\"NDC Code\" />\r\n               \t<label for=\"ndc-radio\"
        class=\"searchoptions\">NDC Code</label>\r\n                <input  class=\"searchoptions\"
        \ type=\"radio\" name=\"searchdb\" value=\"drugclass\" id=\"class-radio\"
        title=\"Drug Class\" />\r\n               \t<label for=\"class-radio\" class=\"searchoptions\">Drug
        Class</label>\r\n                <input  class=\"searchoptions\"  type=\"radio\"
        name=\"searchdb\" value=\"setid\" id=\"setid-radio\" title=\"SETID\" />\r\n
        \              \t<label  for=\"setid-radio\" class=\"searchoptions\">SetId</label>\r\n
        \           </div>\r\n    </div>\r\n    <div class=\"divtr\">\r\n            <div
        class=\"divtd85\">Label Type:</div>\r\n            <div class=\"divtd85\"
        style=\"float:left;\">\r\n                <input class=\"searchoptions\" type=\"radio\"
        name=\"labeltype\" value=\"human\" id=\"human-radio\" title=\"Human Drugs\"
        />\r\n               \t<label for=\"human-radio\" class=\"searchoptions\">Human
        Drugs</label>\r\n                <input class=\"searchoptions\" type=\"radio\"
        name=\"labeltype\" value=\"animal\" id=\"animal-radio\" title=\"Animal Drugs\"
        />\r\n               \t<label for=\"animal-radio\" class=\"searchoptions\">Animal
        Drugs</label>\r\n            </div>\r\n    </div>          \r\n</div>\r\n</form>\r\n\r\n</div>\r\n\r\n\r\n\r\n</div>\r\n\r\n\r\n\r\n\t\t<div
        id=\"rxnormlist\">\r\n\t\t<h3>RxNorm Names</h3>\r\n\t\t\r\n\t\t\t\r\n\t\t\t<ul
        style=\"maring:0px; padding:0px;\">\r\n\t\t\t\t<li id=\"item1\" style=\"padding:1px;
        margin:1px;\">\r\n\t\t\t\t\t  \r\n\t\t\t\t\t\t<a \tid=\"viewrxnorm\"\r\n\t\t\t\t\t\t\thref=\"rxnormdata.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d\"\r\n\t\t\t\t\t\t\tonclick=\"rxnormpopup(this.href);return
        false;\"\r\n\t\t\t\t\t\t\ttarget=\"rxnorm\" title=\"Link to Review RxNorm
        Normal Forms\" >\r\n\t\t\t\t\t\t\t<img src=\"images/closed.gif\"\r\n\t\t\t\t\t\t\t\t
        alt=\"Icon attached Review or Hide All RxNorm Normal Forms Link\"\r\n\t\t\t\t\t\t\t\t
        id=\"img_item1\"\r\n\t\t\t\t\t\t\t\t border=\"0\"\r\n\t\t\t\t\t\t\t\t style=\"clear:none;float:left\">Review
        RxNorm Normal Forms</a>\r\n\t\t\t\t\t  \r\n\t\t\t  \t</li>\r\n\t\t\t </ul>\r\n\t\t\r\n\t\t</div>\r\n\t\r\n\r\n<!DOCTYPE
        html PUBLIC \"-\">\n<p class=\"DocumentTitle\">\n<strong>LEXAPRO\n\t\t\t(escitalopram
        oxalate) \n\t\t tablet</strong>\n<br> [Cardinal Health] \n\t</p><br>\n\r\n<div
        class=\"permalink\">\r\n\t<h3><strong>Permanent Link: </strong></h3><span><a
        href=\"lookup.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d\">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d
        </a><span>\r\n</div>\r\n<div id=\"nlmdrugstatus\">\r\n<table border=\"4\"
        width=\"100%\" style=\"border: 1px solid rgb(142, 1, 10); padding: 0pt; float:
        right; margin-bottom: 0.75em; margin-top: 0.75em; position: relative; right:
        0pt;\">\r\n<thead align=\"left\" bgcolor=\"#F6F6F6\" style=\"color:#8e010a;
        font-size:1.2em\">\r\n<tr>\r\n<th scope=\"col\">\r\n\t<a class=\"anchor1\"
        href=\"http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162063.htm\"
        target=\"fda\"\r\nonclick=\"fdapopup(this.href);return false;\" title=\"Document
        Type including Content of Labeling Type\">\r\nCategory</a></th>\r\n<th scope=\"col\">\r\n\t<a
        class=\"anchor1\" href=\"http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071816.htm\"
        target=\"fda\" onclick=\"fdapopup(this.href);return false;\" title=\"SPL DEA
        Schedule\">\r\nDEA Schedule</a></th>\r\n<th scope=\"col\">\r\n<a class=\"anchor1\"
        href=\"http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071826.htm\"
        target=\"fda\" onclick=\"fdapopup(this.href);return false;\" title=\"Marketing
        Category\">Marketing Status</a></th>\r\n</tr>\r\n</thead>\r\n<tbody>\r\n<tr>\r\n<td
        scope=\"row\"><strong>HUMAN PRESCRIPTION DRUG LABEL</strong></td>\r\n<td scope=\"row\"><strong></strong></td>\r\n<td
        scope=\"row\"><strong>New Drug Application</strong></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<div
        id=\"disclaimer\" >\r\n\t\r\n\t\r\n</div>\r\n</div>\r\n\n<div id=\"dmsectionsfieldset\">\n<fieldset>\n<legend>Drug
        Label Sections</legend>\n<div id=\"dmsections\">\n<ul>\n<li>\n<a title=\"Description\"
        href=\"#nlm34089-3\" class=\"nlmlinktrue\">Description</a>\n</li>\n<li>\n<a
        title=\"Clinical Pharmacology\" href=\"#nlm34090-1\" class=\"nlmlinktrue\">Clinical
        Pharmacology</a>\n</li>\n<li>\n<a title=\"Indications &amp; Usage\" href=\"#nlm34067-9\"
        class=\"nlmlinktrue\">Indications &amp; Usage</a>\n</li>\n<li>\n<a title=\"Contraindications\"
        href=\"#nlm34070-3\" class=\"nlmlinktrue\">Contraindications</a>\n</li>\n<li>\n<a
        title=\"Warnings\" href=\"#nlm43685-7\" class=\"nlmlinktrue\">Warnings</a>\n</li>\n<li>\n<a
        title=\"Precautions\" href=\"#nlm43685-7\" class=\"nlmlinktrue\">Precautions</a>\n</li>\n<li>\n<a
        title=\"Adverse Reactions\" href=\"#nlm34084-4\" class=\"nlmlinktrue\">Adverse
        Reactions</a>\n</li>\n<li>\n<a title=\"Overdosage\" href=\"#nlm34088-5\" class=\"nlmlinktrue\">Overdosage</a>\n</li>\n<li>\n<a
        title=\"Dosage &amp; Administration\" href=\"#nlm34068-7\" class=\"nlmlinktrue\">Dosage
        &amp; Administration</a>\n</li>\n<li>\n<a title=\"How Supplied\" href=\"#nlm34069-5\"
        class=\"nlmlinktrue\">How Supplied</a>\n</li>\n<li>\n<a title=\"Patient Counseling
        Information\" href=\"#nlm34076-0\" class=\"nlmlinktrue\">Patient Counseling
        Information</a>\n</li>\n<li>\n<a title=\"Supplemental Patient Material\" href=\"#nlm38056-8\"
        class=\"nlmlinkfalse\">Supplemental Patient Material</a>\n</li>\n<li>\n<a
        title=\"Boxed Warning\" href=\"#nlm34066-1\" class=\"nlmlinktrue\">Boxed Warning</a>\n</li>\n<li>\n<a
        title=\"Patient Package Insert\" href=\"#nlm42230-3\" class=\"nlmlinkfalse\">Patient
        Package Insert</a>\n</li>\n<li>\n<a title=\"Highlights\" href=\"#nlmhighlights\"
        class=\"nlmlinktrue\">Highlights</a>\n</li>\n<li>\n<a title=\"Full Table of
        Contents\" href=\"javascript:nlmftoc('nlmftoc');\" class=\"nlmlinktrue\">Full
        Table of Contents</a>\n</li>\n<li><a href=\"medguide.cfm?setid=b49f45d7-432f-4529-b382-3a65f7643e2d\"
        \ target=\"medguide\" class=\"nlmlinktrue\">Medication Guide</a></li></ul>\n</div>\n</fieldset>\n</div>\n\r\n<div
        class=\"spl\">\r\n\t\n<a name=\"druglabelcontent\"></a>\n<div id=\"nlmhighlightsmarker\">\n<div
        class=\"Highlights\" id=\"Highlights\">\n<table border=\"0\" style=\"table-layout:fixed\"
        width=\"100%\" cellpadding=\"5\" cellspacing=\"5\">\n<tr>\n<td valign=\"top\"
        align=\"left\" width=\"50%\">\n<div>\n<a name=\"nlmhighlights\">\n<h1>HIGHLIGHTS
        OF PRESCRIBING INFORMATION</h1>\n</a>\n<div class=\"HighlightsDisclaimer\">These
        highlights do not include all the information needed to use Lexapro&reg; safely
        and effectively. See full prescribing information for Lexapro&reg;<br>Lexapro&reg;
        (escitalopram oxalate) Tablets<br>Lexapro&reg; (escitalopram oxalate) Oral
        Solution<br>Initial U.S. Approval: 2002 </div>\n<div class=\"Warning\">\n<div>\n<h1
        class=\"Warning\">\n<span class=\"Bold\">WARNING: Suicidality and Antidepressant
        Drugs</span>\n</h1>\n<h1 class=\"Warning\">\n<span class=\"Bold\"><span class=\"Italics\">See
        full prescribing information for complete boxed warning.</span></span>\n</h1>\n<p
        class=\"Highlights\">\n<span class=\"Bold\">Increased risk of suicidal thinking
        and behavior in children, adolescents and young adults taking antidepressants
        for major depressive disorder (MDD) and other psychiatric disorders. Lexapro
        is not approved for use in pediatric patients less than 12 years of age (<a
        href=\"#i4i_section_ID_s26\">5.1</a>).</span> \n</p>\n</div>\n</div>\n<div></div>\n<div
        class=\"HighlightSection\">\n<h1 class=\"Highlights\">\n<span>INDICATIONS
        AND USAGE</span>\n</h1>\n<div>\n<p class=\"Highlights\">Lexapro&reg; is a
        selective serotonin reuptake inhibitor (SSRI) indicated for:  </p>\n<ul>\n<li>Acute
        and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and
        adolescents aged 12-17 years (<a href=\"#i4i_section_ID_s3\">1.1</a>) </li>\n<li>Acute
        Treatment of Generalized Anxiety Disorder (GAD) in adults (<a href=\"#i4i_section_ID_s4\">1.2</a>)
        </li>\n</ul>\n</div>\n<div></div>\n<div></div>\n</div>\n<div class=\"HighlightSection\">\n<h1
        class=\"Highlights\">\n<span>DOSAGE AND ADMINISTRATION</span>\n</h1>\n<div>\n<p
        class=\"Highlights\">Lexapro should generally be administered once daily,
        morning or evening with or without food (<a href=\"#i4i_section_ID_s6\">2.1</a>,
        <a href=\"#i4i_section_ID_s11\">2.2</a>).  </p>\n<a name=\"id_31f63656-bfee-4735-861d-80a9346ee6b7\"></a>\n<table>\n<col
        align=\"left\" width=\"36.300%\">\n<col align=\"left\" width=\"63.700%\">\n<tbody
        class=\"Headless\">\n<tr class=\"First\">\n<td class=\"Botrule Lrule Rrule
        Toprule\" align=\"left\" valign=\"top\">\n<p class=\"Highlights\">Indication<br>
        \n</p>\n</td><td class=\"Botrule Rrule\" align=\"left\" valign=\"top\">\n<p
        class=\"Highlights\">Recommended Dose<br> \n</p>\n</td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"left\" colspan=\"2\" valign=\"top\">\n<p
        class=\"Highlights\">MDD (<a href=\"#i4i_section_ID_s6\">2.1</a>)<br> \n</p>\n</td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">\n<p class=\"Highlights\">Adolescents
        (<a href=\"#i4i_section_ID_s6\">2.1</a>)<br> \n</p>\n</td><td class=\"Botrule
        Rrule\" align=\"left\" valign=\"top\">\n<p class=\"Highlights\">Initial: 10
        mg once daily<br> \n</p>\n<p class=\"Highlights\">Recommended: 10 mg once
        daily<br> \n</p>\n<p class=\"Highlights\">Maximum: 20 mg once daily<br> \n</p>\n</td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">\n<p class=\"Highlights\">Adults
        (<a href=\"#i4i_section_ID_s6\">2.1</a>)<br> \n</p>\n</td><td class=\"Botrule
        Rrule\" align=\"left\" valign=\"top\">\n<p class=\"Highlights\">Initial: 10
        mg once daily<br> \n</p>\n<p class=\"Highlights\">Recommended: 10 mg once
        daily<br> \n</p>\n<p class=\"Highlights\">Maximum: 20 mg once daily<br> \n</p>\n</td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">\n<p class=\"Highlights\">GAD
        (<a href=\"#i4i_section_ID_s11\">2.2</a>)<br> \n</p>\n</td><td class=\"Botrule
        Rrule\" align=\"left\" valign=\"top\">\n<p class=\"Highlights\">\n<br> \n</p>\n</td>\n</tr>\n<tr
        class=\"Last\">\n<td class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">\n<p
        class=\"Highlights\">Adults (<a href=\"#i4i_section_ID_s11\">2.2</a>)<br>
        \n</p>\n</td><td class=\"Botrule Rrule\" align=\"left\" valign=\"top\">\n<p
        class=\"Highlights\">Initial: 10 mg once daily<br> \n</p>\n<p class=\"Highlights\">Recommended:
        10 mg once daily<br> \n</p>\n</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>No
        additional benefits seen at 20 mg/day dose (<a href=\"#i4i_section_ID_s6\">2.1</a>).
        </li>\n<li>10 mg/day is the recommended dose for most elderly patients and
        patients with hepatic impairment (<a href=\"#i4i_section_ID_s15\">2.3</a>).
        </li>\n<li>No dosage adjustment for patients with mild or moderate renal impairment.
        Use caution in patients with severe renal impairment (<a href=\"#i4i_section_ID_s15\">2.3</a>).
        </li>\n<li>Discontinuing Lexapro: A gradual dose reduction is recommended
        (<a href=\"#i4i_section_ID_s16\">2.4</a>). </li>\n</ul>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n<div></div>\n</div>\n<div>\n<div>\n<div></div>\n</div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n<div
        class=\"HighlightSection\">\n<h1 class=\"Highlights\">\n<span>DOSAGE FORMS
        AND STRENGTHS</span>\n</h1>\n<div>\n<ul>\n<li>Tablets: 5 mg, 10 mg (scored)
        and 20 mg (scored) (<a href=\"#i4i_section_ID_s19\">3.1</a>) </li>\n<li>Oral
        solution: 1 mg per mL (<a href=\"#i4i_section_ID_s20\">3.2</a>) </li>\n</ul>\n</div>\n<div></div>\n<div></div>\n</div>\n<div
        class=\"HighlightSection\">\n<h1 class=\"Highlights\">\n<span>CONTRAINDICATIONS</span>\n</h1>\n<div>\n<ul>\n<li>Monoamine
        Oxidase Inhibitors: Do not use with an MAOI or within 14 days of stopping
        an MAOI. Allow 14 days after stopping Lexapro before starting an MAOI (<a
        href=\"#i4i_section_ID_s22\">4.1</a>, <a href=\"#i4i_section_ID_s36\">5.10</a>).
        </li>\n<li>Pimozide: Do not use concomitantly (<a href=\"#i4i_section_ID_s23\">4.2</a>,
        <a href=\"#i4i_section_ID_s73\">7.10</a>). </li>\n<li>Known hypersensitivity
        to escitalopram or citalopram or any of the inactive ingredients (<a href=\"#i4i_section_ID_s24\">4.3</a>).
        </li>\n</ul>\n</div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n<div
        class=\"HighlightSection\">\n<h1 class=\"Highlights\">\n<span>WARNINGS AND
        PRECAUTIONS</span>\n</h1>\n<div>\n<ul>\n<li>Clinical Worsening/Suicide Risk:
        Monitor for clinical worsening, suicidality and unusual change in behavior,
        especially, during the initial few months of therapy or at times of dose changes
        (<a href=\"#i4i_section_ID_s26\">5.1</a>). </li>\n<li>Serotonin Syndrome or
        Neuroleptic Malignant Syndrome (NMS)-like Reactions: Manage with immediate
        discontinuation and continuing monitoring (<a href=\"#i4i_section_ID_s28\">5.2</a>).
        </li>\n<li>Discontinuation of Treatment with Lexapro: A gradual reduction
        in dose rather than abrupt cessation is recommended whenever possible (<a
        href=\"#i4i_section_ID_s29\">5.3</a>). </li>\n<li>Seizures: Prescribe with
        care in patients with a history of seizure (<a href=\"#i4i_section_ID_s30\">5.4</a>).
        </li>\n<li>Activation of Mania/Hypomania: Use cautiously in patients with
        a history of mania (<a href=\"#i4i_section_ID_s31\">5.5</a>). </li>\n<li>Hyponatremia:
        Can occur in association with SIADH (<a href=\"#i4i_section_ID_s32\">5.6</a>).
        </li>\n<li>Abnormal Bleeding: Use caution in concomitant use with NSAIDs,
        aspirin, warfarin or other drugs that affect coagulation (<a href=\"#i4i_section_ID_s33\">5.7</a>).
        </li>\n<li>Interference with Cognitive and Motor Performance: Use caution
        when operating machinery (<a href=\"#i4i_section_ID_s34\">5.8</a>). </li>\n<li>Use
        in Patients with Concomitant Illness: Use caution in patients with diseases
        or conditions that produce altered metabolism or hemodynamic responses (<a
        href=\"#i4i_section_ID_s35\">5.9</a>). </li>\n</ul>\n</div>\n<div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n<div
        class=\"HighlightSection\">\n<h1 class=\"Highlights\">\n<span>ADVERSE REACTIONS</span>\n</h1>\n<div>\n<p
        class=\"Highlights\">Most commonly observed adverse reactions (incidence &ge;
        5% and at least twice the incidence of placebo patients) are: insomnia, ejaculation
        disorder (primarily ejaculatory delay), nausea, sweating increased, fatigue
        and somnolence, decreased libido, and anorgasmia (<a href=\"#i4i_section_ID_s38\">6.1</a>).
        \ </p>\n<p class=\"Highlights\">\n<span class=\"Bold\">To report SUSPECTED
        ADVERSE REACTIONS, contact Forest Laboratories Inc. at 1-800-678-1605, or
        FDA at 1-800-FDA-1088 or</span><span class=\"Bold\"><span class=\"Underline\"><span
        class=\"Italics\"> www.fda.gov/medwatch </span></span></span>.  </p>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n<div>\n<div></div>\n</div>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n<div>\n<div></div>\n</div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n<div>\n<div></div>\n</div>\n</div>\n<div
        class=\"HighlightSection\">\n<h1 class=\"Highlights\">\n<span>DRUG INTERACTIONS</span>\n</h1>\n<div>\n<p
        class=\"Highlights\">Concomitant use with SSRIs, SNRIs or Tryptophan is not
        recommended (<a href=\"#i4i_section_ID_s64\">7.1</a>).  </p>\n<p class=\"Highlights\">Use
        caution when concomitant use with drugs that affect Hemostasis (NSAIDs, Aspirin,
        Warfarin) (<a href=\"#i4i_section_ID_s69\">7.6</a>).  </p>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n<div
        class=\"HighlightSection\">\n<h1 class=\"Highlights\">\n<span>USE IN SPECIFIC
        POPULATIONS</span>\n</h1>\n<div>\n<p class=\"Highlights\">Pregnancy: Use only
        if the potential benefit justifies the potential risk to the fetus (<a href=\"#i4i_pregnancy_ID_s86\">8.1</a>).
        \ </p>\n<p class=\"Highlights\">Nursing Mothers: Caution should be exercised
        when administered to a nursing woman (<a href=\"#i4i_nursing_mothers_ID_s90\">8.3</a>)
        \ </p>\n<p class=\"Highlights\">Pediatric Use: Safety and effectiveness of
        Lexapro has not been established in pediatric MDD patients less than 12 years
        of age (<a href=\"#i4i_pediatric_use_ID_s91\">8.4</a>).  </p>\n</div>\n<div>\n<div></div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n<div>\n<div>\n<div></div>\n</div>\n</div>\n<div>\n<div></div>\n<div></div>\n</div>\n<div></div>\n<div>\n<div></div>\n<div></div>\n<div>\n<div></div>\n<div></div>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n</div>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n<div>\n<div></div>\n<div></div>\n</div>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n<div></div>\n</div>\n<div>\n<div></div>\n<div>\n<div></div>\n</div>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n</div>\n<div></div>\n</div>\n<div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<div></div>\n<p
        class=\"HighlightsSeeReference\">See 17 for PATIENT COUNSELING INFORMATION
        and Medication Guide.</p>\n<p class=\"HighlightsRevision\">Revised: 08/2013</p>\n</div>\n</td>\n</tr>\n</table>\n</div>\n</div>\n<div
        id=\"nlmftoc\">\n<span id=\"backtodmsections\"><a title=\" Back to Highlights
        and Tabs \" href=\"javascript:nlmftoc('backtodmsections');\">Back to Highlights
        and Tabs</a></span>\n<div class=\"Index\" id=\"Index\">\n<table style=\"table-layout:fixed\"
        width=\"100%\" cellpadding=\"5\" cellspacing=\"5\">\n<tr>\n<td valign=\"top\"
        align=\"left\" width=\"50%\">\n<div>\n<h1 class=\"Colspan\">\n<a style=\"text-decoration:none;\"
        name=\"dmsections\">FULL PRESCRIBING INFORMATION: CONTENTS</a><a name=\"footnote-reference-content\"
        href=\"#footnote-content\">*</a>\n</h1>\n<h1>\n<a href=\"#section-1\" class=\"toc\">WARNINGS:
        SUICIDALITY AND ANTIDEPRESSANT DRUGS </a>\n</h1>\n<h1>\n<a href=\"#section-1\"
        class=\"toc\">1 INDICATIONS AND USAGE</a>\n</h1>\n<h2>\n<a href=\"#section-1.1\"
        class=\"toc\">1.1 Major Depressive Disorder </a>\n</h2>\n<h2>\n<a href=\"#section-1.2\"
        class=\"toc\">1.2 Generalized Anxiety Disorder </a>\n</h2>\n<h1>\n<a href=\"#section-2\"
        class=\"toc\">2 DOSAGE AND ADMINISTRATION</a>\n</h1>\n<h2>\n<a href=\"#section-2.1\"
        class=\"toc\">2.1 Major Depressive Disorder </a>\n</h2>\n<h2>\n<a href=\"#section-2.2\"
        class=\"toc\">2.2 Generalized Anxiety Disorder </a>\n</h2>\n<h2>\n<a href=\"#section-2.3\"
        class=\"toc\">2.3 Special Populations </a>\n</h2>\n<h2>\n<a href=\"#section-2.4\"
        class=\"toc\">2.4 Discontinuation of Treatment with Lexapro </a>\n</h2>\n<h2>\n<a
        href=\"#section-2.5\" class=\"toc\">2.5 Switching Patients To or From a Monoamine
        Oxidase Inhibitor </a>\n</h2>\n<h1>\n<a href=\"#section-3\" class=\"toc\">3
        DOSAGE FORMS AND STRENGTHS</a>\n</h1>\n<h2>\n<a href=\"#section-3.1\" class=\"toc\">3.1
        Tablets </a>\n</h2>\n<h2>\n<a href=\"#section-3.2\" class=\"toc\">3.2 Oral
        Solution </a>\n</h2>\n<h1>\n<a href=\"#section-4\" class=\"toc\">4 CONTRAINDICATIONS</a>\n</h1>\n<h2>\n<a
        href=\"#section-4.1\" class=\"toc\">4.1 Monoamine oxidase inhibitors (MAOIs)
        </a>\n</h2>\n<h2>\n<a href=\"#section-4.2\" class=\"toc\">4.2 Pimozide </a>\n</h2>\n<h2>\n<a
        href=\"#section-4.3\" class=\"toc\">4.3 Hypersensitivity to escitalopram or
        citalopram </a>\n</h2>\n<h1>\n<a href=\"#section-5\" class=\"toc\">5 WARNINGS
        AND PRECAUTIONS</a>\n</h1>\n<h2>\n<a href=\"#section-5.1\" class=\"toc\">5.1
        Clinical Worsening and Suicide Risk </a>\n</h2>\n<h2>\n<a href=\"#section-5.2\"
        class=\"toc\">5.2 Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like
        Reactions </a>\n</h2>\n<h2>\n<a href=\"#section-5.3\" class=\"toc\">5.3 Discontinuation
        of Treatment with Lexapro </a>\n</h2>\n<h2>\n<a href=\"#section-5.4\" class=\"toc\">5.4
        Seizures </a>\n</h2>\n<h2>\n<a href=\"#section-5.5\" class=\"toc\">5.5 Activation
        of Mania/Hypomania </a>\n</h2>\n<h2>\n<a href=\"#section-5.6\" class=\"toc\">5.6
        Hyponatremia </a>\n</h2>\n<h2>\n<a href=\"#section-5.7\" class=\"toc\">5.7
        Abnormal Bleeding </a>\n</h2>\n<h2>\n<a href=\"#section-5.8\" class=\"toc\">5.8
        Interference with Cognitive and Motor Performance </a>\n</h2>\n<h2>\n<a href=\"#section-5.9\"
        class=\"toc\">5.9 Use in Patients with Concomitant Illness </a>\n</h2>\n<h2>\n<a
        href=\"#section-5.10\" class=\"toc\">5.10 Potential for Interaction with Monoamine
        Oxidase Inhibitors </a>\n</h2>\n<h1>\n<a href=\"#section-6\" class=\"toc\">6
        ADVERSE REACTIONS</a>\n</h1>\n<h2>\n<a href=\"#section-6.1\" class=\"toc\">6.1
        Clinical Trials Experience </a>\n</h2>\n<h2>\n<a href=\"#section-6.2\" class=\"toc\">6.2
        Post-Marketing Experience </a>\n</h2>\n<h1>\n<a href=\"#section-7\" class=\"toc\">7
        DRUG INTERACTIONS</a>\n</h1>\n<h2>\n<a href=\"#section-7.1\" class=\"toc\">7.1
        Serotonergic Drugs </a>\n</h2>\n<h2>\n<a href=\"#section-7.2\" class=\"toc\">7.2
        Triptans </a>\n</h2>\n<h2>\n<a href=\"#section-7.3\" class=\"toc\">7.3 CNS
        Drugs </a>\n</h2>\n<h2>\n<a href=\"#section-7.4\" class=\"toc\">7.4 Alcohol
        </a>\n</h2>\n<h2>\n<a href=\"#section-7.5\" class=\"toc\">7.5 Monoamine Oxidase
        Inhibitors (MAOIs) </a>\n</h2>\n<h2>\n<a href=\"#section-7.6\" class=\"toc\">7.6
        Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.) </a>\n</h2>\n<h2>\n<a
        href=\"#section-7.7\" class=\"toc\">7.7 Cimetidine </a>\n</h2>\n<h2>\n<a href=\"#section-7.8\"
        class=\"toc\">7.8 Digoxin </a>\n</h2>\n<h2>\n<a href=\"#section-7.9\" class=\"toc\">7.9
        Lithium </a>\n</h2>\n<h2>\n<a href=\"#section-7.10\" class=\"toc\">7.10 Pimozide
        and Celexa </a>\n</h2>\n<h2>\n<a href=\"#section-7.11\" class=\"toc\">7.11
        Sumatriptan </a>\n</h2>\n<h2>\n<a href=\"#section-7.12\" class=\"toc\">7.12
        Theophylline </a>\n</h2>\n<h2>\n<a href=\"#section-7.13\" class=\"toc\">7.13
        Warfarin </a>\n</h2>\n<h2>\n<a href=\"#section-7.14\" class=\"toc\">7.14 Carbamazepine
        </a>\n</h2>\n<h2>\n<a href=\"#section-7.15\" class=\"toc\">7.15 Triazolam
        </a>\n</h2>\n<h2>\n<a href=\"#section-7.16\" class=\"toc\">7.16 Ketoconazole
        </a>\n</h2>\n<h2>\n<a href=\"#section-7.17\" class=\"toc\">7.17 Ritonavir
        </a>\n</h2>\n<h2>\n<a href=\"#section-7.18\" class=\"toc\">7.18 CYP3A4 and
        -2C19 Inhibitors </a>\n</h2>\n<h2>\n<a href=\"#section-7.19\" class=\"toc\">7.19
        Drugs Metabolized by Cytochrome P4502D6 </a>\n</h2>\n<h2>\n<a href=\"#section-7.20\"
        class=\"toc\">7.20 Metoprolol </a>\n</h2>\n<h2>\n<a href=\"#section-7.21\"
        class=\"toc\">7.21 Electroconvulsive Therapy (ECT) </a>\n</h2>\n<h1>\n<a href=\"#section-8\"
        class=\"toc\">8 USE IN SPECIFIC POPULATIONS</a>\n</h1>\n<h2>\n<a href=\"#section-8.1\"
        class=\"toc\">8.1 Pregnancy</a>\n</h2>\n<h2>\n<a href=\"#section-8.2\" class=\"toc\">8.2
        Labor and Delivery</a>\n</h2>\n<h2>\n<a href=\"#section-8.3\" class=\"toc\">8.3
        Nursing Mothers</a>\n</h2>\n<h2>\n<a href=\"#section-8.4\" class=\"toc\">8.4
        Pediatric Use</a>\n</h2>\n<h2>\n<a href=\"#section-8.5\" class=\"toc\">8.5
        Geriatric Use</a>\n</h2>\n<h1>\n<a href=\"#section-9\" class=\"toc\">9 DRUG
        ABUSE AND DEPENDENCE</a>\n</h1>\n<h2>\n<a href=\"#section-9.1\" class=\"toc\">9.2
        Abuse and Dependence </a>\n</h2>\n<h1>\n<a href=\"#section-10\" class=\"toc\">10
        OVERDOSAGE</a>\n</h1>\n<h2>\n<a href=\"#section-10.1\" class=\"toc\">10.1
        Human Experience </a>\n</h2>\n<h2>\n<a href=\"#section-10.2\" class=\"toc\">10.2
        Management of Overdose </a>\n</h2>\n<h1>\n<a href=\"#section-11\" class=\"toc\">11
        DESCRIPTION</a>\n</h1>\n<h1>\n<a href=\"#section-12\" class=\"toc\">12 CLINICAL
        PHARMACOLOGY</a>\n</h1>\n<h2>\n<a href=\"#section-12.1\" class=\"toc\">12.1
        Mechanism of Action</a>\n</h2>\n<h2>\n<a href=\"#section-12.2\" class=\"toc\">12.2
        Pharmacodynamics</a>\n</h2>\n<h2>\n<a href=\"#section-12.3\" class=\"toc\">12.3
        Pharmacokinetics</a>\n</h2>\n<h1>\n<a href=\"#section-13\" class=\"toc\">13
        NONCLINICAL TOXICOLOGY</a>\n</h1>\n<h2>\n<a href=\"#section-13.1\" class=\"toc\">13.1
        Carcinogenesis, Mutagenesis, Impairment of Fertility</a>\n</h2>\n<h2>\n<a
        href=\"#section-13.2\" class=\"toc\">13.2 Animal Toxicology and/or Pharmacology</a>\n</h2>\n<h1>\n<a
        href=\"#section-14\" class=\"toc\">14 CLINICAL STUDIES</a>\n</h1>\n<h2>\n<a
        href=\"#section-14.1\" class=\"toc\">14.1 Major Depressive Disorder </a>\n</h2>\n<h2>\n<a
        href=\"#section-14.2\" class=\"toc\">14.2 Generalized Anxiety Disorder </a>\n</h2>\n<h1>\n<a
        href=\"#section-15\" class=\"toc\">16 HOW SUPPLIED/STORAGE AND HANDLING</a>\n</h1>\n<h2>\n<a
        href=\"#section-15.1\" class=\"toc\">16.1 Tablets </a>\n</h2>\n<h2>\n<a href=\"#section-15.2\"
        class=\"toc\">16.2 Oral Solution </a>\n</h2>\n<h1>\n<a href=\"#section-16\"
        class=\"toc\">17 PATIENT COUNSELING INFORMATION </a>\n</h1>\n<h2>\n<a href=\"#section-16.1\"
        class=\"toc\">17.1 Information for Patients </a>\n</h2>\n<h1>\n<a href=\"#section-18\"
        class=\"toc\">Principal Display Panel - 10 mg</a>\n</h1>\n<h1>\n<a href=\"#section-19\"
        class=\"toc\">Principal Display Panel - 10 mg</a>\n</h1>\n<h1>\n<a href=\"#section-20\"
        class=\"toc\">Principal Display Panel - 20 mg</a>\n</h1>\n<h1>\n<a href=\"#section-21\"
        class=\"toc\">Principal Display Panel - 20 mg</a>\n</h1>\n<h1>\n<a href=\"#section-22\"
        class=\"toc\">Principal Display Panel - 20 mg</a>\n</h1>\n<dl class=\"Footnote\">\n<dt>\n<a
        name=\"footnote-content\" href=\"#footnote-reference-content\">*</a>\n</dt>\n<dd>Sections
        or subsections omitted from the full prescribing information are not listed.</dd>\n</dl>\n</div>\n</td>\n</tr>\n</table>\n</div>\n</div>\n<div
        class=\"Contents\">\n<h1>FULL PRESCRIBING INFORMATION</h1>\n<div class=\"Section\"
        data-sectionCode=\"48780-1\">\n<a name=\"section-1\"></a>\n<p></p>\n</div>\n<a
        name=\"nlm34066-1\"></a>\n\n<div class=\"Warning\">\n<a name=\"s1\"></a><a
        name=\"section-1\"></a>\n<p></p>\n<h1>\n<a></a>WARNINGS: SUICIDALITY AND ANTIDEPRESSANT
        DRUGS </h1>\n<p class=\"First\">\n<span class=\"Bold\">Antidepressants increased
        the risk compared to placebo of suicidal thinking and behavior (suicidality)
        in children, adolescents, and young adults in short-term studies of major
        depressive disorder (MDD) and other psychiatric disorders. Anyone considering
        the use of Lexapro or any other antidepressant in a child, adolescent, or
        young adult must balance this risk with the clinical need. Short-term studies
        did not show an increase in the risk of suicidality with antidepressants compared
        to placebo in adults beyond age 24; there was a reduction in risk with antidepressants
        compared to placebo in adults aged 65 and older. Depression and certain other
        psychiatric disorders are themselves associated with increases in the risk
        of suicide. Patients of all ages who are started on antidepressant therapy
        should be monitored appropriately and observed closely for clinical worsening,
        suicidality, or unusual changes in behavior. Families and caregivers should
        be advised of the need for close observation and communication with the prescriber.
        Lexapro is not approved for use in pediatric patients less than 12 years of
        age.</span><span class=\"Bold\"><span class=\"Italics\">[See Warnings and
        Precautions: Clinical Worsening and Suicide Risk (<a href=\"#i4i_section_ID_s26\">5.1</a>),
        Patient Counseling Information: Information for Patients (<a href=\"#i4i_info_patients_duplicate_ID_s132\">17.1</a>),
        and Used in Specific Populations: Pediatric Use (<a href=\"#i4i_pediatric_use_ID_s91\">8.4</a>)].</span></span>\n</p>\n</div>\n\n<div
        class=\"Section\" data-sectionCode=\"34067-9\">\n<a name=\"i4i_indications_ID_s2\"></a><a
        name=\"section-1\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34067-9\"></a>1 INDICATIONS
        AND USAGE</h1>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s3\"></a><a
        name=\"section-1.1\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>1.1 Major
        Depressive Disorder </h2>\n<p class=\"First\"> Lexapro (escitalopram) is indicated
        for the acute and maintenance treatment of major depressive disorder in adults
        and in adolescents 12 to 17 years of age [<span class=\"Italics\">see Clinical
        Studies (<a href=\"#i4i_section_ID_s123\">14.1</a>)</span>]. </p>\n<p>A major
        depressive episode (DSM-IV) implies a prominent and relatively persistent
        (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually
        interferes with daily functioning, and includes at least five of the following
        nine symptoms: depressed mood, loss of interest in usual activities, significant
        change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation
        or retardation, increased fatigue, feelings of guilt or worthlessness, slowed
        thinking or impaired concentration, a suicide attempt or suicidal ideation.
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s4\"></a><a
        name=\"section-1.2\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>1.2 Generalized
        Anxiety Disorder </h2>\n<p class=\"First\">Lexapro is indicated for the acute
        treatment of Generalized Anxiety Disorder (GAD) in adults [<span class=\"Italics\">see
        Clinical Studies (<a href=\"#i4i_section_ID_s126\">14.2</a>)</span>]. </p>\n<p>Generalized
        Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry
        (apprehensive expectation) that is persistent for at least 6 months and which
        the person finds difficult to control. It must be associated with at least
        3 of the following symptoms: restlessness or feeling keyed up or on edge,
        being easily fatigued, difficulty concentrating or mind going blank, irritability,
        muscle tension, and sleep disturbance. </p>\n</div>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"34068-7\">\n<a name=\"i4i_dosage_admin_ID_s5\"></a><a name=\"section-2\"></a>\n<p></p>\n<h1>\n<a
        name=\"nlm34068-7\"></a>2 DOSAGE AND ADMINISTRATION</h1>\n<p class=\"First\">Lexapro
        should be administered once daily, in the morning or evening, with or without
        food. </p>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s6\"></a><a
        name=\"section-2.1\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>2.1 Major
        Depressive Disorder </h2>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s7\"></a><a name=\"section-2.1.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Initial Treatment</span>\n</p>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s8\"></a><a
        name=\"section-2.1.1.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Adolescents</span>\n</p>\n<p>
        The recommended dose of Lexapro is 10 mg once daily. A flexible-dose trial
        of Lexapro (10 to 20 mg/day) demonstrated the effectiveness of Lexapro [<span
        class=\"Italics\">see Clinical Studies (<a href=\"#i4i_section_ID_s123\">14.1</a>)</span>].
        If the dose is increased to 20 mg, this should occur after a minimum of three
        weeks. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s9\"></a><a name=\"section-2.1.1.2\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Adults</span>\n</p>\n<p>The recommended
        dose of Lexapro is 10 mg once daily. A fixed-dose trial of Lexapro demonstrated
        the effectiveness of both 10 mg and 20 mg of Lexapro, but failed to demonstrate
        a greater benefit of 20 mg over 10 mg [<span class=\"Italics\">see Clinical
        Studies (<a href=\"#i4i_section_ID_s123\">14.1</a>)</span>]. If the dose is
        increased to 20 mg, this should occur after a minimum of one week. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s10\"></a><a
        name=\"section-2.1.2\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Maintenance
        Treatment</span>\n</p>\n<p>It is generally agreed that acute episodes of major
        depressive disorder require several months or longer of sustained pharmacological
        therapy beyond response to the acute episode. Systematic evaluation of continuing
        Lexapro 10 or 20 mg/day in adults patients with major depressive disorder
        who responded while taking Lexapro during an 8-week, acute-treatment phase
        demonstrated a benefit of such maintenance treatment [see Clinical Studies
        (<a href=\"#i4i_section_ID_s123\">14.1</a>)]. Nevertheless, the physician
        who elects to use Lexapro for extended periods should periodically re-evaluate
        the long-term usefulness of the drug for the individual patient. Patients
        should be periodically reassessed to determine the need for maintenance treatment.
        </p>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s11\"></a><a name=\"section-2.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>2.2 Generalized Anxiety Disorder </h2>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s12\"></a><a name=\"section-2.2.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Initial Treatment</span>\n</p>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s13\"></a><a
        name=\"section-2.2.1.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Adults</span>\n</p>\n<p>The
        recommended starting dose of Lexapro is 10 mg once daily. If the dose is increased
        to 20 mg, this should occur after a minimum of one week. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s14\"></a><a
        name=\"section-2.2.2\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Maintenance
        Treatment</span>\n</p>\n<p>Generalized anxiety disorder is recognized as a
        chronic condition. The efficacy of Lexapro in the treatment of GAD beyond
        8 weeks has not been systematically studied. The physician who elects to use
        Lexapro for extended periods should periodically re-evaluate the long-term
        usefulness of the drug for the individual patient. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s15\"></a><a
        name=\"section-2.3\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>2.3 Special
        Populations </h2>\n<p class=\"First\">10 mg/day is the recommended dose for
        most elderly patients and patients with hepatic impairment. </p>\n<p>No dosage
        adjustment is necessary for patients with mild or moderate renal impairment.
        Lexapro should be used with caution in patients with severe renal impairment.
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s16\"></a><a
        name=\"section-2.4\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>2.4 Discontinuation
        of Treatment with Lexapro </h2>\n<p class=\"First\">Symptoms associated with
        discontinuation of Lexapro and other SSRIs and SNRIs have been reported [<span
        class=\"Italics\">see Warnings and Precautions (<a href=\"#i4i_section_ID_s29\">5.3</a>)</span>].
        Patients should be monitored for these symptoms when discontinuing treatment.
        A gradual reduction in the dose rather than abrupt cessation is recommended
        whenever possible. If intolerable symptoms occur following a decrease in the
        dose or upon discontinuation of treatment, then resuming the previously prescribed
        dose may be considered. Subsequently, the physician may continue decreasing
        the dose but at a more gradual rate. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s17\"></a><a name=\"section-2.5\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>2.5 Switching Patients To or From a Monoamine Oxidase
        Inhibitor </h2>\n<p class=\"First\">At least 14 days should elapse between
        discontinuation of an MAOI and initiation of Lexapro therapy. Similarly, at
        least 14 days should be allowed after stopping Lexapro before starting an
        MAOI [<span class=\"Italics\">see Contraindications (<a href=\"#i4i_section_ID_s22\">4.1</a>)
        and Warnings and Precautions (<a href=\"#i4i_section_ID_s36\">5.10</a>)</span>].
        </p>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"43678-2\">\n<a
        name=\"i4i_dosage_form_strength_ID_s18\"></a><a name=\"section-3\"></a>\n<p></p>\n<h1>\n<a
        name=\"nlm43678-2\"></a>3 DOSAGE FORMS AND STRENGTHS</h1>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s19\"></a><a name=\"section-3.1\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>3.1 Tablets </h2>\n<p class=\"First\">Lexapro tablets
        are film-coated, round tablets containing escitalopram oxalate in strengths
        equivalent to 5 mg, 10 mg and 20 mg escitalopram base. The 10 and 20 mg tablets
        are scored. Imprinted with \"FL\" on one side and either \"5\", &ldquo;10&rdquo;,
        or &ldquo;20&rdquo; on the other side according to their respective strengths.
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s20\"></a><a
        name=\"section-3.2\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>3.2 Oral
        Solution </h2>\n<p class=\"First\">Lexapro oral solution contains escitalopram
        oxalate equivalent to 1 mg/mL escitalopram base. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"34070-3\">\n<a name=\"i4i_contraindications_ID_s21\"></a><a
        name=\"section-4\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34070-3\"></a>4 CONTRAINDICATIONS</h1>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s22\"></a><a
        name=\"section-4.1\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>4.1 Monoamine
        oxidase inhibitors (MAOIs) </h2>\n<p class=\"First\">Concomitant use in patients
        taking monoamine oxidase inhibitors (MAOIs) is contraindicated [<span class=\"Italics\">see
        Warnings and Precautions (<a href=\"#i4i_section_ID_s36\">5.10</a>)</span>].
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s23\"></a><a
        name=\"section-4.2\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>4.2 Pimozide
        </h2>\n<p class=\"First\">Concomitant use in patients taking pimozide is contraindicated
        [<span class=\"Italics\">see Drug Interactions (<a href=\"#i4i_section_ID_s73\">7.10</a>)</span>].
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s24\"></a><a
        name=\"section-4.3\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>4.3 Hypersensitivity
        to escitalopram or citalopram </h2>\n<p class=\"First\">Lexapro is contraindicated
        in patients with a hypersensitivity to escitalopram or citalopram or any of
        the inactive ingredients in Lexapro. </p>\n</div>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"43685-7\">\n<a name=\"i4i_warnings_precautions_ID_s25\"></a><a
        name=\"section-5\"></a>\n<p></p>\n<h1>\n<a name=\"nlm43685-7\"></a>5 WARNINGS
        AND PRECAUTIONS</h1>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s26\"></a><a name=\"section-5.1\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>5.1 Clinical Worsening and Suicide Risk </h2>\n<p
        class=\"First\">Patients with major depressive disorder (MDD), both adult
        and pediatric, may experience worsening of their depression and/or the emergence
        of suicidal ideation and behavior (suicidality) or unusual changes in behavior,
        whether or not they are taking antidepressant medications, and this risk may
        persist until significant remission occurs. Suicide is a known risk of depression
        and certain other psychiatric disorders, and these disorders themselves are
        the strongest predictors of suicide. There has been a long-standing concern,
        however, that antidepressants may have a role in inducing worsening of depression
        and the emergence of suicidality in certain patients during the early phases
        of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant
        drugs (SSRIs and others) showed that these drugs increase the risk of suicidal
        thinking and behavior (suicidality) in children, adolescents, and young adults
        (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders.
        Short-term studies did not show an increase in the risk of suicidality with
        antidepressants compared to placebo in adults beyond age 24; there was a reduction
        with antidepressants compared to placebo in adults aged 65 and older. </p>\n<p>The
        pooled analyses of placebo-controlled trials in children and adolescents with
        MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included
        a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients.
        The pooled analyses of placebo-controlled trials in adults with MDD or other
        psychiatric disorders included a total of 295 short-term trials (median duration
        of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was
        considerable variation in risk of suicidality among drugs, but a tendency
        toward an increase in the younger patients for almost all drugs studied. There
        were differences in absolute risk of suicidality across the different indications,
        with the highest incidence in MDD. The risk differences (drug vs. placebo),
        however, were relatively stable within age strata and across indications.
        These risk differences (drug-placebo difference in the number of cases of
        suicidality per 1000 patients treated) are provided in <span class=\"Bold\"><a
        href=\"#t1\">Table 1</a>.</span>\n</p>\n<a name=\"t1\"></a>\n<table>\n<caption>\n<span>TABLE
        1 </span>\n</caption>\n<col align=\"left\" width=\"34.550%\">\n<col align=\"left\"
        width=\"65.450%\">\n<tbody class=\"Headless\">\n<tr class=\"First\">\n<td
        class=\"Botrule Lrule Rrule Toprule\" align=\"center\" valign=\"top\"><span
        class=\"Bold\">Age Range</span></td><td class=\"Botrule Rrule\" align=\"center\"
        valign=\"top\"><span class=\"Bold\">Drug-Placebo Difference in Number of Cases
        of Suicidality per 1000 Patients Treated</span></td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">Increases Compared to Placebo </td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"center\" valign=\"top\">&lt;18 </td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">14 additional cases
        </td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule\" align=\"center\" valign=\"top\">18-24
        </td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">5 additional
        cases </td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule\" align=\"center\"
        valign=\"top\"></td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">Decreases
        Compared to Placebo </td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule\"
        align=\"center\" valign=\"top\">25-64 </td><td class=\"Botrule Rrule\" align=\"center\"
        valign=\"top\">1 fewer case </td>\n</tr>\n<tr class=\"Last\">\n<td class=\"Botrule
        Lrule Rrule\" align=\"center\" valign=\"top\">&ge;65 </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">6 fewer cases </td>\n</tr>\n</tbody>\n</table>\n<p>No
        suicides occurred in any of the pediatric trials. There were suicides in the
        adult trials, but the number was not sufficient to reach any conclusion about
        drug effect on suicide. </p>\n<p>It is unknown whether the suicidality risk
        extends to longer-term use, i.e., beyond several months. However, there is
        substantial evidence from placebo-controlled maintenance trials in adults
        with depression that the use of antidepressants can delay the recurrence of
        depression. </p>\n<p>All patients being treated with antidepressants for any
        indication should be monitored appropriately and observed closely for clinical
        worsening, suicidality, and unusual changes in behavior, especially during
        the initial few months of a course of drug therapy, or at times of dose changes,
        either increases or decreases. </p>\n<p>The following symptoms, anxiety, agitation,
        panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity,
        akathisia (psychomotor restlessness), hypomania, and mania, have been reported
        in adult and pediatric patients being treated with antidepressants for major
        depressive disorder as well as for other indications, both psychiatric and
        nonpsychiatric. Although a causal link between the emergence of such symptoms
        and either the worsening of depression and/or the emergence of suicidal impulses
        has not been established, there is concern that such symptoms may represent
        precursors to emerging suicidality. </p>\n<p>Consideration should be given
        to changing the therapeutic regimen, including possibly discontinuing the
        medication, in patients whose depression is persistently worse, or who are
        experiencing emergent suicidality or symptoms that might be precursors to
        worsening depression or suicidality, especially if these symptoms are severe,
        abrupt in onset, or were not part of the patient's presenting symptoms. </p>\n<p>If
        the decision has been made to discontinue treatment, medication should be
        tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation
        can be associated with certain symptoms [<span class=\"Italics\">see Dosage
        and Administration (<a href=\"#i4i_section_ID_s16\">2.4</a>)</span>]. </p>\n<p>Families
        and caregivers of patients being treated with antidepressants for major depressive
        disorder or other indications, both psychiatric and nonpsychiatric, should
        be alerted about the need to monitor patients for the emergence of agitation,
        irritability, unusual changes in behavior, and the other symptoms described
        above, as well as the emergence of suicidality, and to report such symptoms
        immediately to health care providers. Such monitoring should include daily
        observation by families and caregivers [<span class=\"Italics\">see also Patient
        Counseling Information (<a href=\"#i4i_info_patients_duplicate_ID_s132\">17.1</a>)</span>].
        Prescriptions for Lexapro should be written for the smallest quantity of tablets
        consistent with good patient management, in order to reduce the risk of overdose.
        </p>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s27\"></a><a
        name=\"section-5.1.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Screening
        Patients for Bipolar Disorder</span>\n</p>\n<p>A major depressive episode
        may be the initial presentation of bipolar disorder. It is generally believed
        (though not established in controlled trials) that treating such an episode
        with an antidepressant alone may increase the likelihood of precipitation
        of a mixed/manic episode in patients at risk for bipolar disorder. Whether
        any of the symptoms described above represent such a conversion is unknown.
        However, prior to initiating treatment with an antidepressant, patients with
        depressive symptoms should be adequately screened to determine if they are
        at risk for bipolar disorder; such screening should include a detailed psychiatric
        history, including a family history of suicide, bipolar disorder, and depression.
        It should be noted that Lexapro is not approved for use in treating bipolar
        depression. </p>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s28\"></a><a name=\"section-5.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>5.2 Serotonin Syndrome or Neuroleptic Malignant Syndrome
        (NMS)-like Reactions </h2>\n<p class=\"First\"> The development of a potentially
        life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like
        reactions have been reported with SNRIs and SSRIs alone, including Lexapro
        treatment, but particularly with concomitant use of serotonergic drugs (including
        triptans) with drugs which impair metabolism of serotonin (including MAOIs),
        or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms
        may include mental status changes (e.g., agitation, hallucinations, coma),
        autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia),
        neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal
        symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most
        severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia,
        muscle rigidity, autonomic instability with possible rapid fluctuation of
        vital signs, and mental status changes. Patients should be monitored for the
        emergence of serotonin syndrome or NMS-like signs and symptoms. </p>\n<p>The
        concomitant use of Lexapro with MAOIs intended to treat depression is contraindicated.
        If concomitant treatment of Lexapro with a 5-hydroxytryptamine receptor agonist
        (triptan) is clinically warranted, careful observation of the patient is advised,
        particularly during treatment initiation and dose increases. </p>\n<p>The
        concomitant use of Lexapro with serotonin precursors (such as tryptophan)
        is not recommended. Treatment with Lexapro and any concomitant serotonergic
        or antidopaminergic agents, including antipsychotics, should be discontinued
        immediately if the above events occur and supportive symptomatic treatment
        should be initiated. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s29\"></a><a name=\"section-5.3\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>5.3 Discontinuation of Treatment with Lexapro </h2>\n<p
        class=\"First\">During marketing of Lexapro and other SSRIs and SNRIs (serotonin
        and norepinephrine reuptake inhibitors), there have been spontaneous reports
        of adverse events occurring upon discontinuation of these drugs, particularly
        when abrupt, including the following: dysphoric mood, irritability, agitation,
        dizziness, sensory disturbances (e.g., paresthesias such as electric shock
        sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia,
        and hypomania. While these events are generally self-limiting, there have
        been reports of serious discontinuation symptoms. </p>\n<p>Patients should
        be monitored for these symptoms when discontinuing treatment with Lexapro.
        A gradual reduction in the dose rather than abrupt cessation is recommended
        whenever possible. If intolerable symptoms occur following a decrease in the
        dose or upon discontinuation of treatment, then resuming the previously prescribed
        dose may be considered. Subsequently, the physician may continue decreasing
        the dose but at a more gradual rate [<span class=\"Italics\">see Dosage and
        Administration (<a href=\"#i4i_section_ID_s16\">2.4</a>)</span>]. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s30\"></a><a
        name=\"section-5.4\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>5.4 Seizures
        </h2>\n<p class=\"First\">Although anticonvulsant effects of racemic citalopram
        have been observed in animal studies, Lexapro has not been systematically
        evaluated in patients with a seizure disorder. These patients were excluded
        from clinical studies during the product's premarketing testing. In clinical
        trials of Lexapro, cases of convulsion have been reported in association with
        Lexapro treatment. Like other drugs effective in the treatment of major depressive
        disorder, Lexapro should be introduced with care in patients with a history
        of seizure disorder. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s31\"></a><a name=\"section-5.5\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>5.5 Activation of Mania/Hypomania </h2>\n<p class=\"First\">In
        placebo-controlled trials of Lexapro in major depressive disorder, activation
        of mania/hypomania was reported in one (0.1%) of 715 patients treated with
        Lexapro and in none of the 592 patients treated with placebo. One additional
        case of hypomania has been reported in association with Lexapro treatment.
        Activation of mania/hypomania has also been reported in a small proportion
        of patients with major affective disorders treated with racemic citalopram
        and other marketed drugs effective in the treatment of major depressive disorder.
        As with all drugs effective in the treatment of major depressive disorder,
        Lexapro should be used cautiously in patients with a history of mania. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s32\"></a><a
        name=\"section-5.6\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>5.6 Hyponatremia
        </h2>\n<p class=\"First\"> Hyponatremia may occur as a result of treatment
        with SSRIs and SNRIs, including Lexapro. In many cases, this hyponatremia
        appears to be the result of the syndrome of inappropriate antidiuretic hormone
        secretion (SIADH), and was reversible when Lexapro was discontinued. Cases
        with serum sodium lower than 110 mmol/L have been reported. Elderly patients
        may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also,
        patients taking diuretics or who are otherwise volume depleted may be at greater
        risk [<span class=\"Italics\">see Geriatric Use (<a href=\"#i4i_geriatric_use_ID_s92\">8.5</a></span>)].
        Discontinuation of Lexapro should be considered in patients with symptomatic
        hyponatremia and appropriate medical intervention should be instituted. </p>\n<p>
        Signs and symptoms of hyponatremia include headache, difficulty concentrating,
        memory impairment, confusion, weakness, and unsteadiness, which may lead to
        falls. Signs and symptoms associated with more severe and/or acute cases have
        included hallucination, syncope, seizure, coma, respiratory arrest, and death.
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s33\"></a><a
        name=\"section-5.7\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>5.7 Abnormal
        Bleeding </h2>\n<p class=\"First\"> SSRIs and SNRIs, including Lexapro, may
        increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal
        anti-inflammatory drugs, warfarin, and other anticoagulants may add to the
        risk. Case reports and epidemiological studies (case-control and cohort design)
        have demonstrated an association between use of drugs that interfere with
        serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding
        events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas,
        epistaxis, and petechiae to life-threatening hemorrhages. </p>\n<p>Patients
        should be cautioned about the risk of bleeding associated with the concomitant
        use of Lexapro and NSAIDs, aspirin, or other drugs that affect coagulation.
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s34\"></a><a
        name=\"section-5.8\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>5.8 Interference
        with Cognitive and Motor Performance </h2>\n<p class=\"First\">In a study
        in normal volunteers, Lexapro 10 mg/day did not produce impairment of intellectual
        function or psychomotor performance. Because any psychoactive drug may impair
        judgment, thinking, or motor skills, however, patients should be cautioned
        about operating hazardous machinery, including automobiles, until they are
        reasonably certain that Lexapro therapy does not affect their ability to engage
        in such activities. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s35\"></a><a name=\"section-5.9\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>5.9 Use in Patients with Concomitant Illness </h2>\n<p
        class=\"First\">Clinical experience with Lexapro in patients with certain
        concomitant systemic illnesses is limited. Caution is advisable in using Lexapro
        in patients with diseases or conditions that produce altered metabolism or
        hemodynamic responses. </p>\n<p>Lexapro has not been systematically evaluated
        in patients with a recent history of myocardial infarction or unstable heart
        disease. Patients with these diagnoses were generally excluded from clinical
        studies during the product's premarketing testing. </p>\n<p>In subjects with
        hepatic impairment, clearance of racemic citalopram was decreased and plasma
        concentrations were increased. The recommended dose of Lexapro in hepatically
        impaired patients is 10 mg/day [<span class=\"Italics\">see Dosage and Administration
        (<a href=\"#i4i_section_ID_s15\">2.3</a>)</span>]. </p>\n<p>Because escitalopram
        is extensively metabolized, excretion of unchanged drug in urine is a minor
        route of elimination. Until adequate numbers of patients with severe renal
        impairment have been evaluated during chronic treatment with Lexapro, however,
        it should be used with caution in such patients [<span class=\"Italics\">see
        Dosage and Administration (<a href=\"#i4i_section_ID_s15\">2.3</a>)</span>].
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s36\"></a><a
        name=\"section-5.10\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>5.10
        Potential for Interaction with Monoamine Oxidase Inhibitors </h2>\n<p class=\"First\">In
        patients receiving serotonin reuptake inhibitor drugs in combination with
        a monoamine oxidase inhibitor (MAOI), there have been reports of serious,
        sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic
        instability with possible rapid fluctuations of vital signs, and mental status
        changes that include extreme agitation progressing to delirium and coma. These
        reactions have also been reported in patients who have recently discontinued
        SSRI treatment and have been started on an MAOI. Some cases presented with
        features resembling neuroleptic malignant syndrome. Furthermore, limited animal
        data on the effects of combined use of SSRIs and MAOIs suggest that these
        drugs may act synergistically to elevate blood pressure and evoke behavioral
        excitation. Therefore, it is recommended that Lexapro should not be used in
        combination with an MAOI, or within 14 days of discontinuing treatment with
        an MAOI. Similarly, at least 14 days should be allowed after stopping Lexapro
        before starting an MAOI. </p>\n<p>Serotonin syndrome has been reported in
        two patients who were concomitantly receiving linezolid, an antibiotic which
        is a reversible non-selective MAOI. </p>\n</div>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"34084-4\">\n<a name=\"i4i_adverse_effects_ID_s37\"></a><a
        name=\"section-6\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34084-4\"></a>6 ADVERSE
        REACTIONS</h1>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s38\"></a><a
        name=\"section-6.1\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>6.1 Clinical
        Trials Experience </h2>\n<p class=\"First\">Because clinical studies are conducted
        under widely varying conditions, adverse reaction rates observed in the clinical
        studies of a drug cannot be directly compared to rates in the clinical studies
        of another drug and may not reflect the rates observed in practice. </p>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s39\"></a><a
        name=\"section-6.1.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Clinical
        Trial Data Sources</span>\n</p>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s40\"></a><a name=\"section-6.1.1.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Pediatrics (6 -17 years)</span>\n</p>\n<p>Adverse
        events were collected in 576 pediatric patients (286 Lexapro, 290 placebo)
        with major depressive disorder in double-blind placebo-controlled studies.
        Safety and effectiveness of Lexapro in pediatric patients less than 12 years
        of age has not been established. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s41\"></a><a name=\"section-6.1.1.2\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Adults</span>\n</p>\n<p>Adverse events
        information for Lexapro was collected from 715 patients with major depressive
        disorder who were exposed to escitalopram and from 592 patients who were exposed
        to placebo in double-blind, placebo-controlled trials. An additional 284 patients
        with major depressive disorder were newly exposed to escitalopram in open-label
        trials. The adverse event information for Lexapro in patients with GAD was
        collected from 429 patients exposed to escitalopram and from 427 patients
        exposed to placebo in double-blind, placebo-controlled trials. </p>\n<p>Adverse
        events during exposure were obtained primarily by general inquiry and recorded
        by clinical investigators using terminology of their own choosing. Consequently,
        it is not possible to provide a meaningful estimate of the proportion of individuals
        experiencing adverse events without first grouping similar types of events
        into a smaller number of standardized event categories. In the tables and
        tabulations that follow, standard World Health Organization (WHO) terminology
        has been used to classify reported adverse events. </p>\n<p>The stated frequencies
        of adverse reactions represent the proportion of individuals who experienced,
        at least once, a treatment-emergent adverse event of the type listed. An event
        was considered treatment-emergent if it occurred for the first time or worsened
        while receiving therapy following baseline evaluation. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s42\"></a><a
        name=\"section-6.1.2\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Adverse
        Events Associated with Discontinuation of Treatment</span>\n</p>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s43\"></a><a name=\"section-6.1.2.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Major Depressive Disorder</span>\n</p>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s44\"></a><a
        name=\"section-6.1.2.1.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Pediatrics
        (6 -17 years)</span>\n</p>\n<p>Adverse events were associated with discontinuation
        of 3.5% of 286 patients receiving Lexapro and 1% of 290 patients receiving
        placebo. The most common adverse event (incidence at least 1% for Lexapro
        and greater than placebo) associated with discontinuation was insomnia (1%
        Lexapro, 0% placebo). </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s45\"></a><a name=\"section-6.1.2.1.2\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Adults</span>\n</p>\n<p>Among the 715
        depressed patients who received Lexapro in placebo-controlled trials, 6% discontinued
        treatment due to an adverse event, as compared to 2% of 592 patients receiving
        placebo. In two fixed-dose studies, the rate of discontinuation for adverse
        events in patients receiving 10 mg/day Lexapro was not significantly different
        from the rate of discontinuation for adverse events in patients receiving
        placebo. The rate of discontinuation for adverse events in patients assigned
        to a fixed dose of 20 mg/day Lexapro was 10%, which was significantly different
        from the rate of discontinuation for adverse events in patients receiving
        10 mg/day Lexapro (4%) and placebo (3%). Adverse events that were associated
        with the discontinuation of at least 1% of patients treated with Lexapro,
        and for which the rate was at least twice that of placebo, were nausea (2%)
        and ejaculation disorder (2% of male patients). </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s46\"></a><a
        name=\"section-6.1.2.2\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Generalized
        Anxiety Disorder</span>\n</p>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s47\"></a><a name=\"section-6.1.2.2.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Adults</span>\n</p>\n<p>Among the 429
        GAD patients who received Lexapro 10-20 mg/day in placebo-controlled trials,
        8% discontinued treatment due to an adverse event, as compared to 4% of 427
        patients receiving placebo. Adverse events that were associated with the discontinuation
        of at least 1% of patients treated with Lexapro, and for which the rate was
        at least twice the placebo rate, were nausea (2%), insomnia (1%), and fatigue
        (1%). </p>\n</div>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s48\"></a><a name=\"section-6.1.3\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Incidence of Adverse Reactions in Placebo-Controlled
        Clinical Trials</span>\n</p>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s49\"></a><a name=\"section-6.1.3.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Major Depressive Disorder</span>\n</p>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s50\"></a><a
        name=\"section-6.1.3.1.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Pediatrics
        (6 -17 years)</span>\n</p>\n<p>The overall profile of adverse reactions in
        pediatric patients was generally similar to that seen in adult studies, as
        shown in <a href=\"#t2\">Table 2</a>. However, the following adverse reactions
        (excluding those which appear in <a href=\"#t2\">Table 2</a> and those for
        which the coded terms were uninformative or misleading) were reported at an
        incidence of at least 2% for Lexapro and greater than placebo: back pain,
        urinary tract infection, vomiting, and nasal congestion. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s51\"></a><a
        name=\"section-6.1.3.1.2\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Adults</span>\n</p>\n<p>The
        most commonly observed adverse reactions in Lexapro patients (incidence of
        approximately 5% or greater and approximately twice the incidence in placebo
        patients) were insomnia, ejaculation disorder (primarily ejaculatory delay),
        nausea, sweating increased, fatigue, and somnolence. </p>\n<p>\n<a href=\"#t2\">Table
        2</a> enumerates the incidence, rounded to the nearest percent, of treatment-emergent
        adverse events that occurred among 715 depressed patients who received Lexapro
        at doses ranging from 10 to 20 mg/day in placebo-controlled trials. Events
        included are those occurring in 2% or more of patients treated with Lexapro
        and for which the incidence in patients treated with Lexapro was greater than
        the incidence in placebo-treated patients. </p>\n<a name=\"t2\"></a>\n<table>\n<caption>\n<span>TABLE
        2 Treatment-Emergent Adverse Reactions observed with a frequency of &ge; 2%
        and greater than placebo for Major Depressive Disorder </span>\n</caption>\n<col
        align=\"left\" width=\"44.552%\">\n<col align=\"left\" width=\"28.324%\">\n<col
        align=\"left\" width=\"27.124%\">\n<tfoot>\n<tr>\n<td align=\"left\" colspan=\"3\"
        valign=\"top\">\n<p class=\"First\">\n<span class=\"Sup\">1</span>Primarily
        ejaculatory delay. </p>\n</td>\n</tr>\n<tr>\n<td align=\"left\" colspan=\"3\"
        valign=\"top\">\n<p class=\"First\">\n<span class=\"Sup\">2</span>Denominator
        used was for males only (N=225 Lexapro; N=188 placebo). </p>\n</td>\n</tr>\n<tr
        class=\"Last\">\n<td class=\"Botrule Lrule\" align=\"left\" colspan=\"3\"
        valign=\"top\">\n<p class=\"First\">\n<span class=\"Sup\">3</span>Denominator
        used was for females only (N=490 Lexapro; N=404 placebo). </p>\n</td>\n</tr>\n</tfoot>\n<tbody
        class=\"Headless\">\n<tr class=\"First\">\n<td class=\"Botrule Toprule\" align=\"left\"
        valign=\"top\"><span class=\"Underline\"><span class=\"Bold\">Adverse Reaction</span></span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"><span class=\"Underline\"><span
        class=\"Bold\">Lexapro</span></span></td><td class=\"Botrule\" align=\"center\"
        valign=\"top\"><span class=\"Underline\"><span class=\"Bold\">Placebo</span></span></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"><span class=\"Bold\">(N=715)<br>%</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">(N=592)<br>%</span></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\"><span class=\"Bold\">Autonomic
        Nervous System Disorders</span></td><td class=\"Botrule\" align=\"center\"
        valign=\"top\"></td><td class=\"Botrule\" align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">Dry Mouth </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">6% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">5% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">Sweating Increased </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">5% </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\"><span
        class=\"Bold\">Central &amp; Peripheral Nervous System Disorders</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">Dizziness </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">5% </td><td class=\"Botrule\" align=\"center\" valign=\"top\">3%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\"><span
        class=\"Bold\">Gastrointestinal Disorders</span></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td><td class=\"Botrule\" align=\"center\"
        valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\">Nausea
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">15% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">7% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">Diarrhea </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">8% </td><td class=\"Botrule\" align=\"center\" valign=\"top\">5%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\">Constipation
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">3% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">Indigestion </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">3% </td><td class=\"Botrule\" align=\"center\" valign=\"top\">1%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\">Abdominal
        Pain </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2% </td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\"><span class=\"Bold\">General</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">Influenza-like Symptoms </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">5% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">4% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">Fatigue </td><td class=\"Botrule\" align=\"center\" valign=\"top\">5%
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\"><span class=\"Bold\">Psychiatric
        Disorders</span></td><td class=\"Botrule\" align=\"center\" valign=\"top\"></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">Insomnia </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">9% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">4% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">Somnolence </td><td class=\"Botrule\" align=\"center\" valign=\"top\">6%
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">Appetite Decreased </td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">3% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">Libido Decreased </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">3% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\"><span class=\"Bold\">Respiratory System Disorders</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">Rhinitis </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">5% </td><td class=\"Botrule\" align=\"center\" valign=\"top\">4%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\">Sinusitis
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">3% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">2% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\"><span class=\"Bold\">Urogenital</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">Ejaculation Disorder<span class=\"Sup\">1,2</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">9% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">&lt;1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">Impotence<span class=\"Sup\">2</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">3% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">&lt;1% </td>\n</tr>\n<tr class=\"Last\">\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">Anorgasmia<span class=\"Sup\">3</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">2% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">&lt;1% </td>\n</tr>\n</tbody>\n</table>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s52\"></a><a
        name=\"section-6.1.3.2\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Generalized
        Anxiety Disorder</span>\n</p>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s53\"></a><a name=\"section-6.1.3.2.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Adults</span>\n</p>\n<p>The most commonly
        observed adverse reactions in Lexapro patients (incidence of approximately
        5% or greater and approximately twice the incidence in placebo patients) were
        nausea, ejaculation disorder (primarily ejaculatory delay), insomnia, fatigue,
        decreased libido, and anorgasmia. </p>\n<p>\n<span class=\"Bold\"><a href=\"#t3\">Table
        3</a></span> enumerates the incidence, rounded to the nearest percent of treatment-emergent
        adverse events that occurred among 429 GAD patients who received Lexapro 10
        to 20 mg/day in placebo-controlled trials. Events included are those occurring
        in 2% or more of patients treated with Lexapro and for which the incidence
        in patients treated with Lexapro was greater than the incidence in placebo-treated
        patients. </p>\n<a name=\"t3\"></a>\n<table>\n<caption>\n<span>TABLE 3 Treatment-Emergent
        Adverse Reactions observed with a frequency of &ge; 2% and greater than placebo
        for Generalized Anxiety Disorder </span>\n</caption>\n<col align=\"left\"
        width=\"47.833%\">\n<col align=\"left\" width=\"26.133%\">\n<col align=\"left\"
        width=\"26.033%\">\n<tfoot>\n<tr>\n<td align=\"left\" colspan=\"3\" valign=\"top\">\n<p
        class=\"First\">\n<span class=\"Sup\">1</span>Primarily ejaculatory delay.
        </p>\n</td>\n</tr>\n<tr>\n<td align=\"left\" colspan=\"3\" valign=\"top\">\n<p
        class=\"First\">\n<span class=\"Sup\">2</span>Denominator used was for males
        only (N=182 Lexapro; N=195 placebo). </p>\n</td>\n</tr>\n<tr class=\"Last\">\n<td
        class=\"Botrule Lrule\" align=\"left\" colspan=\"3\" valign=\"top\">\n<p class=\"First\">\n<span
        class=\"Sup\">3</span>Denominator used was for females only (N=247 Lexapro;
        N=232 placebo). </p>\n</td>\n</tr>\n</tfoot>\n<tbody class=\"Headless\">\n<tr
        class=\"First\">\n<td class=\"Botrule Toprule\" align=\"left\" valign=\"top\"><span
        class=\"Underline\"><span class=\"Bold\">Adverse Reactions</span></span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"><span class=\"Underline\"><span
        class=\"Bold\">Lexapro</span></span></td><td class=\"Botrule\" align=\"center\"
        valign=\"top\"><span class=\"Underline\"><span class=\"Bold\">Placebo</span></span></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\"></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"><span class=\"Bold\">(N=429)<br>%</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">(N=427)<br>%</span></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\"><span class=\"Bold\">Autonomic
        Nervous System Disorders</span></td><td class=\"Botrule\" align=\"center\"
        valign=\"top\"></td><td class=\"Botrule\" align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Dry Mouth
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">9% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">5% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Sweating Increased </td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">4% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\"><span class=\"Bold\">Central &amp; Peripheral
        Nervous System Disorders</span></td><td class=\"Botrule\" align=\"center\"
        valign=\"top\"></td><td class=\"Botrule\" align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Headache
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">24% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">17% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Paresthesia </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">2% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\"><span class=\"Bold\">Gastrointestinal Disorders</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Nausea </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">18% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">8% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">&nbsp;&nbsp;&nbsp;Diarrhea </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">8% </td><td class=\"Botrule\" align=\"center\" valign=\"top\">6%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Constipation
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">5% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">4% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Indigestion </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">3% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">2% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">&nbsp;&nbsp;&nbsp;Vomiting </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">3% </td><td class=\"Botrule\" align=\"center\" valign=\"top\">1%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Abdominal
        Pain </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2% </td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Flatulence
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Toothache </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">2% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">0% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\"><span class=\"Bold\">General</span></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td><td class=\"Botrule\" align=\"center\"
        valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Fatigue
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">8% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">2% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Influenza-like Symptoms </td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">5% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">4% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\"><span class=\"Bold\">Musculoskeletal System
        Disorder</span></td><td class=\"Botrule\" align=\"center\" valign=\"top\"></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Neck/Shoulder
        Pain </td><td class=\"Botrule\" align=\"center\" valign=\"top\">3% </td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\"><span class=\"Bold\">Psychiatric
        Disorders</span></td><td class=\"Botrule\" align=\"center\" valign=\"top\"></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Somnolence
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">13% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">7% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Insomnia </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">12% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">6% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">&nbsp;&nbsp;&nbsp;Libido Decreased </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">7% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">2% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">&nbsp;&nbsp;&nbsp;Dreaming Abnormal </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">3% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">2% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">&nbsp;&nbsp;&nbsp;Appetite Decreased </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">3% </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\"
        valign=\"top\">&nbsp;&nbsp;&nbsp;Lethargy </td><td class=\"Botrule\" align=\"center\"
        valign=\"top\">3% </td><td class=\"Botrule\" align=\"center\" valign=\"top\">1%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\"><span
        class=\"Bold\">Respiratory System Disorders</span></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td><td class=\"Botrule\" align=\"center\"
        valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Yawning
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2% </td><td class=\"Botrule\"
        align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\"><span class=\"Bold\">Urogenital</span></td><td
        class=\"Botrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule\"
        align=\"center\" valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule\"
        align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Ejaculation Disorder<span
        class=\"Sup\">1,2</span></td><td class=\"Botrule\" align=\"center\" valign=\"top\">14%
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Anorgasmia<span
        class=\"Sup\">3</span></td><td class=\"Botrule\" align=\"center\" valign=\"top\">6%
        </td><td class=\"Botrule\" align=\"center\" valign=\"top\">&lt;1% </td>\n</tr>\n<tr
        class=\"Last\">\n<td class=\"Botrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Menstrual
        Disorder </td><td class=\"Botrule\" align=\"center\" valign=\"top\">2% </td><td
        class=\"Botrule\" align=\"center\" valign=\"top\">1% </td>\n</tr>\n</tbody>\n</table>\n</div>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s54\"></a><a
        name=\"section-6.1.4\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Dose
        Dependency of Adverse Reactions</span>\n</p>\n<p>The potential dose dependency
        of common adverse reactions (defined as an incidence rate of &ge;5% in either
        the 10 mg or 20 mg Lexapro groups) was examined on the basis of the combined
        incidence of adverse reactions in two fixed-dose trials. The overall incidence
        rates of adverse events in 10 mg Lexapro-treated patients (66%) was similar
        to that of the placebo-treated patients (61%), while the incidence rate in
        20 mg/day Lexapro-treated patients was greater (86%). <a href=\"#t4\">Table
        4</a> shows common adverse reactions that occurred in the 20 mg/day Lexapro
        group with an incidence that was approximately twice that of the 10 mg/day
        Lexapro group and approximately twice that of the placebo group. </p>\n<a
        name=\"t4\"></a>\n<table>\n<caption>\n<span>TABLE 4 Incidence of Common Adverse
        Reactions in Patients with Major Depressive Disorder </span>\n</caption>\n<col
        align=\"left\" width=\"32.500%\">\n<col align=\"left\" width=\"20.625%\">\n<col
        align=\"left\" width=\"25.000%\">\n<col align=\"left\" width=\"21.875%\">\n<tbody
        class=\"Headless\">\n<tr class=\"First\">\n<td class=\"Botrule Lrule Rrule
        Toprule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Adverse Reaction</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Placebo</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">10
        mg/day</span></td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\"><span
        class=\"Bold\">20 mg/day</span></td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule
        Rrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule Rrule\" align=\"center\"
        valign=\"top\"><span class=\"Bold\">(N=311)</span></td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Lexapro</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Lexapro</span></td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule Rrule\" align=\"center\"
        valign=\"top\"><span class=\"Bold\">(N=310)</span></td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">(N=125)</span></td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Insomnia</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">4% </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">7% </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">14% </td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Diarrhea</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">5% </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">6% </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">14% </td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Dry Mouth</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">3% </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">4% </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">9% </td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Somnolence</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">1% </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">4% </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">9% </td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Dizziness</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">2% </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">4% </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">7% </td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Sweating
        Increased</span></td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">&lt;1%
        </td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">3% </td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">8% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Constipation</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">1% </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">3% </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">6% </td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Fatigue</span></td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">2% </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">2% </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">6% </td>\n</tr>\n<tr class=\"Last\">\n<td
        class=\"Botrule Lrule Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Indigestion</span></td><td
        class=\"Rrule\" align=\"center\" valign=\"top\">1% </td><td class=\"Rrule\"
        align=\"center\" valign=\"top\">2% </td><td class=\"Botrule Rrule\" align=\"center\"
        valign=\"top\">6% </td>\n</tr>\n</tbody>\n</table>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s55\"></a><a name=\"section-6.1.5\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Male and Female Sexual Dysfunction
        with SSRIs</span>\n</p>\n<p>Although changes in sexual desire, sexual performance,
        and sexual satisfaction often occur as manifestations of a psychiatric disorder,
        they may also be a consequence of pharmacologic treatment. In particular,
        some evidence suggests that SSRIs can cause such untoward sexual experiences.
        </p>\n<p>Reliable estimates of the incidence and severity of untoward experiences
        involving sexual desire, performance, and satisfaction are difficult to obtain,
        however, in part because patients and physicians may be reluctant to discuss
        them. Accordingly, estimates of the incidence of untoward sexual experience
        and performance cited in product labeling are likely to underestimate their
        actual incidence. </p>\n<a name=\"t5\"></a>\n<table>\n<caption>\n<span>TABLE
        5 Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials </span>\n</caption>\n<col
        align=\"left\" width=\"35.000%\">\n<col align=\"left\" width=\"32.067%\">\n<col
        align=\"left\" width=\"32.933%\">\n<tbody class=\"Headless\">\n<tr class=\"First\">\n<td
        class=\"Botrule Lrule Rrule Toprule\" align=\"center\" valign=\"top\"><span
        class=\"Bold\">Adverse Event</span></td><td class=\"Botrule Rrule\" align=\"center\"
        valign=\"top\"><span class=\"Bold\">Lexapro</span></td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\"><span class=\"Bold\">Placebo</span></td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule
        Rrule\" align=\"center\" colspan=\"2\" valign=\"top\">In Males Only </td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"center\" valign=\"top\"></td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">(N=407) </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">(N=383) </td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"left\" valign=\"top\">Ejaculation Disorder<br>(primarily
        ejaculatory delay) </td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">\n<br>12%
        </td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">\n<br>1%
        </td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">Libido
        Decreased </td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">6%
        </td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">2% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">&nbsp;&nbsp;&nbsp;Impotence
        </td><td class=\"Botrule Rrule\" align=\"center\" valign=\"top\">2% </td><td
        class=\"Botrule Rrule\" align=\"center\" valign=\"top\">&lt;1% </td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\"></td><td class=\"Botrule
        Rrule\" align=\"center\" colspan=\"2\" valign=\"top\">In Females Only </td>\n</tr>\n<tr>\n<td
        class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\"></td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">(N=737) </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">(N=636) </td>\n</tr>\n<tr>\n<td class=\"Botrule
        Lrule Rrule\" align=\"left\" valign=\"top\">Libido Decreased </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">3% </td><td class=\"Botrule Rrule\"
        align=\"center\" valign=\"top\">1% </td>\n</tr>\n<tr class=\"Last\">\n<td
        class=\"Botrule Lrule Rrule\" align=\"left\" valign=\"top\">Anorgasmia </td><td
        class=\"Rrule\" align=\"center\" valign=\"top\">3% </td><td class=\"Botrule
        Rrule\" align=\"center\" valign=\"top\">&lt;1% </td>\n</tr>\n</tbody>\n</table>\n<p>There
        are no adequately designed studies examining sexual dysfunction with escitalopram
        treatment. </p>\n<p>Priapism has been reported with all SSRIs. </p>\n<p>While
        it is difficult to know the precise risk of sexual dysfunction associated
        with the use of SSRIs, physicians should routinely inquire about such possible
        side effects. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s56\"></a><a name=\"section-6.1.6\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Vital Sign Changes</span>\n</p>\n<p>Lexapro
        and placebo groups were compared with respect to (1) mean change from baseline
        in vital signs (pulse, systolic blood pressure, and diastolic blood pressure)
        and (2) the incidence of patients meeting criteria for potentially clinically
        significant changes from baseline in these variables. These analyses did not
        reveal any clinically important changes in vital signs associated with Lexapro
        treatment. In addition, a comparison of supine and standing vital sign measures
        in subjects receiving Lexapro indicated that Lexapro treatment is not associated
        with orthostatic changes. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s57\"></a><a name=\"section-6.1.7\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Weight Changes</span>\n</p>\n<p>Patients
        treated with Lexapro in controlled trials did not differ from placebo-treated
        patients with regard to clinically important change in body weight. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s58\"></a><a
        name=\"section-6.1.8\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Laboratory
        Changes</span>\n</p>\n<p>Lexapro and placebo groups were compared with respect
        to (1) mean change from baseline in various serum chemistry, hematology, and
        urinalysis variables, and (2) the incidence of patients meeting criteria for
        potentially clinically significant changes from baseline in these variables.
        These analyses revealed no clinically important changes in laboratory test
        parameters associated with Lexapro treatment. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s59\"></a><a name=\"section-6.1.9\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">ECG Changes</span>\n</p>\n<p>Electrocardiograms
        from Lexapro (N=625) and placebo (N=527) groups were compared with respect
        to outliers defined as subjects with QTc changes over 60 msec from baseline
        or absolute values over 500 msec post-dose, and subjects with heart rate increases
        to over 100 bpm or decreases to less than 50 bpm with a 25% change from baseline
        (tachycardic or bradycardic outliers, respectively). None of the patients
        in the Lexapro group had a QTcF interval &gt;500 msec or a prolongation &gt;60
        msec compared to 0.2% of patients in the placebo group. The incidence of tachycardic
        outliers was 0.2% in the Lexapro and the placebo group. The incidence of bradycardic
        outliers was 0.5% in the Lexapro group and 0.2% in the placebo group. </p>\n<p>QTcF
        interval was evaluated in a randomized, placebo and active (moxifloxacin 400
        mg) controlled cross-over, escalating multiple-dose study in 113 healthy subjects.
        The maximum mean <span class=\"Underline\">(95% upper confidence bound) </span>difference
        from placebo arm were 4.5 (6.4) and 10.7 (12.7) msec for 10 mg and supratherapeutic
        30 mg escitalopram given once daily, respectively. Based on the established
        exposure-response relationship, the predicted QTcF change from placebo arm
        (95% confidence interval) under the C<span class=\"Sub\">max</span> for the
        dose of 20 mg is 6.6 (7.9) msec. Escitalopram 30 mg given once daily resulted
        in mean C<span class=\"Sub\">max</span> of 1.7-fold higher than the mean C<span
        class=\"Sub\">max</span> for the maximum recommended therapeutic dose at steady
        state (20 mg). The exposure under supratherapeutic 30 mg dose is similar to
        the steady state concentrations expected in CYP2C19 poor metabolizers following
        a therapeutic dose of 20 mg. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s60\"></a><a name=\"section-6.1.10\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Other Reactions Observed During the
        Premarketing Evaluation of Lexapro</span>\n</p>\n<p>Following is a list of
        treatment-emergent adverse events, as defined in the introduction to the <span
        class=\"Bold\"><a href=\"#i4i_adverse_effects_ID_s37\">ADVERSE REACTIONS</a></span>
        section, reported by the 1428 patients treated with Lexapro for periods of
        up to one year in double-blind or open-label clinical trials during its premarketing
        evaluation. The listing does not include those events already listed in <span
        class=\"Bold\"><a href=\"#t2\">Tables 2</a> &amp; <a href=\"#t3\">3</a></span>,
        those events for which a drug cause was remote and at a rate less than 1%
        or lower than placebo, those events which were so general as to be uninformative,
        and those events reported only once which did not have a substantial probability
        of being acutely life threatening. Events are categorized by body system.
        Events of major clinical importance are described in the Warnings and Precautions
        section (<a href=\"#i4i_warnings_precautions_ID_s25\">5</a>). </p>\n<p>Cardiovascular
        - hypertension, palpitation. </p>\n<p>Central and Peripheral Nervous System
        Disorders - light-headed feeling, migraine. </p>\n<p>Gastrointestinal Disorders
        - abdominal cramp, heartburn, gastroenteritis. </p>\n<p>General - allergy,
        chest pain, fever, hot flushes, pain in limb. </p>\n<p>Metabolic and Nutritional
        Disorders - increased weight. </p>\n<p>Musculoskeletal System Disorders -
        arthralgia, myalgia jaw stiffness. </p>\n<p>Psychiatric Disorders - appetite
        increased, concentration impaired, irritability. </p>\n<p>Reproductive Disorders/Female
        - menstrual cramps, menstrual disorder. </p>\n<p>Respiratory System Disorders
        - bronchitis, coughing, nasal congestion, sinus congestion, sinus headache.
        </p>\n<p>Skin and Appendages Disorders - rash. </p>\n<p>Special Senses - vision
        blurred, tinnitus. </p>\n<p>Urinary System Disorders - urinary frequency,
        urinary tract infection. </p>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s61\"></a><a name=\"section-6.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>6.2 Post-Marketing Experience </h2>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s62\"></a><a name=\"section-6.2.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Adverse Reactions Reported Subsequent
        to the Marketing of Escitalopram</span>\n</p>\n<p>The following additional
        adverse reactions have been identified from spontaneous reports of escitalopram
        received worldwide. These adverse reactions have been chosen for inclusion
        because of a combination of seriousness, frequency of reporting, or potential
        causal connection to escitalopram and have not been listed elsewhere in labeling.
        However, because these adverse reactions were reported voluntarily from a
        population of uncertain size, it is not always possible to reliably estimate
        their frequency or establish a causal relationship to drug exposure. These
        events include: </p>\n<p>Blood and Lymphatic System Disorders: anemia, agranulocytis,
        aplastic anemia, hemolytic anemia, idiopathic thrombocytopenia purpura, leukopenia,
        thrombocytopenia. </p>\n<p>Cardiac Disorders: atrial fibrillation, bradycardia,
        cardiac failure, myocardial infarction, tachycardia, torsade de pointes, ventricular
        arrhythmia, ventricular tachycardia. </p>\n<p>Ear and labyrinth disorders:
        vertigo </p>\n<p>Endocrine Disorders: diabetes mellitus, hyperprolactinemia,
        SIADH. </p>\n<p>Eye Disorders: diplopia, glaucoma, mydriasis, visual disturbance.
        </p>\n<p>Gastrointestinal Disorder: dysphagia, gastrointestinal hemorrhage,
        gastroesophageal reflux, pancreatitis, rectal hemorrhage. </p>\n<p>General
        Disorders and Administration Site Conditions: abnormal gait, asthenia, edema,
        fall, feeling abnormal, malaise. </p>\n<p>Hepatobiliary Disorders: fulminant
        hepatitis, hepatic failure, hepatic necrosis, hepatitis. </p>\n<p>Immune System
        Disorders: allergic reaction, anaphylaxis. </p>\n<p>Investigations: bilirubin
        increased, decreased weight, electrocardiogram QT prolongation, hepatic enzymes
        increased,hypercholesterolemia, INR increased, prothrombin decreased. </p>\n<p>Metabolism
        and Nutrition Disorders: hyperglycemia, hypoglycemia, hypokalemia, hyponatremia.
        </p>\n<p>Musculoskeletal and Connective Tissue Disorders: muscle cramp, muscle
        stiffness, muscle weakness, rhabdomyolysis. </p>\n<p>Nervous System Disorders:
        akathisia, amnesia, ataxia, choreoathetosis, cerebrovascular accident, dysarthria,
        dyskinesia, dystonia, extrapyramidal disorders, grand mal seizures (or convulsions),
        hypoaesthesia, myoclonus, nystagmus, Parkinsonism, restless legs, seizures,
        syncope, tardive dyskinesia, tremor. </p>\n<p>Pregnancy, Puerperium and Perinatal
        Conditions: spontaneous abortion. </p>\n<p>Psychiatric Disorders: acute psychosis,
        aggression, agitation, anger, anxiety, apathy, completed suicide, confusion,
        depersonalization, depression aggravated, delirium, delusion, disorientation,
        feeling unreal, hallucinations (visual and auditory), mood swings, nervousness,
        nightmare, panic reaction, paranoia, restlessness, self-harm or thoughts of
        self-harm, suicide attempt, suicidal ideation, suicidal tendency. </p>\n<p>Renal
        and Urinary Disorders: acute renal failure, dysuria, urinary retention. </p>\n<p>Reproductive
        System and Breast Disorders: menorrhagia, priapism. </p>\n<p>Respiratory,
        Thoracic and Mediastinal Disorders: dyspnea, epistaxis, pulmonary embolism,
        pulmonary hypertension of the newborn. </p>\n<p>Skin and Subcutaneous Tissue
        Disorders: alopecia, angioedema, dermatitis, ecchymosis, erythema multiforme,
        photosensitivity reaction, Stevens Johnson Syndrome, toxic epidermal necrolysis,
        urticaria. </p>\n<p>Vascular Disorders: deep vein thrombosis, flushing, hypertensive
        crisis, hypotension, orthostatic hypotension, phlebitis, thrombosis. </p>\n</div>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"34073-7\">\n<a name=\"i4i_interactions_ID_s63\"></a><a
        name=\"section-7\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34073-7\"></a>7 DRUG
        INTERACTIONS</h1>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s64\"></a><a name=\"section-7.1\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.1 Serotonergic Drugs </h2>\n<p class=\"First\">Based
        on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential
        for serotonin syndrome, caution is advised when Lexapro is coadministered
        with other drugs that may affect the serotonergic neurotransmitter systems,
        such as triptans, linezolid (an antibiotic which is a reversible non-selective
        MAOI), lithium, tramadol, or St. John's Wort [<span class=\"Italics\">see
        Warnings and Precautions (<a href=\"#i4i_section_ID_s28\">5.2</a>)</span>].
        The concomitant use of Lexapro with other SSRIs, SNRIs or tryptophan is not
        recommended. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s65\"></a><a name=\"section-7.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.2 Triptans </h2>\n<p class=\"First\">There have
        been rare postmarketing reports of serotonin syndrome with use of an SSRI
        and a triptan. If concomitant treatment of Lexapro with a triptan is clinically
        warranted, careful observation of the patient is advised, particularly during
        treatment initiation and dose increases [<span class=\"Italics\">see Warnings
        and Precautions (<a href=\"#i4i_section_ID_s28\">5.2</a>)</span>]. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s66\"></a><a
        name=\"section-7.3\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>7.3 CNS
        Drugs </h2>\n<p class=\"First\">Given the primary CNS effects of escitalopram,
        caution should be used when it is taken in combination with other centrally
        acting drugs. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s67\"></a><a name=\"section-7.4\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.4 Alcohol </h2>\n<p class=\"First\">Although Lexapro
        did not potentiate the cognitive and motor effects of alcohol in a clinical
        trial, as with other psychotropic medications, the use of alcohol by patients
        taking Lexapro is not recommended. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s68\"></a><a name=\"section-7.5\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.5 Monoamine Oxidase Inhibitors (MAOIs) </h2>\n<p
        class=\"First\">\n<span class=\"Italics\">[see Contraindications (<a href=\"#i4i_section_ID_s22\">4.1</a>)
        and Warnings and Precautions (<a href=\"#i4i_section_ID_s36\">5.10</a>)].</span>\n</p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s69\"></a><a
        name=\"section-7.6\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>7.6 Drugs
        That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.) </h2>\n<p
        class=\"First\">Serotonin release by platelets plays an important role in
        hemostasis. Epidemiological studies of the case-control and cohort design
        that have demonstrated an association between use of psychotropic drugs that
        interfere with serotonin reuptake and the occurrence of upper gastrointestinal
        bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate
        the risk of bleeding. Altered anticoagulant effects, including increased bleeding,
        have been reported when SSRIs and SNRIs are coadministered with warfarin.
        Patients receiving warfarin therapy should be carefully monitored when Lexapro
        is initiated or discontinued. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s70\"></a><a name=\"section-7.7\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.7 Cimetidine </h2>\n<p class=\"First\">In subjects
        who had received 21 days of 40 mg/day racemic citalopram, combined administration
        of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram
        AUC and C<span class=\"Sub\">max</span> of 43% and 39%, respectively. The
        clinical significance of these findings is unknown. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s71\"></a><a name=\"section-7.8\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.8 Digoxin </h2>\n<p class=\"First\">In subjects
        who had received 21 days of 40 mg/day racemic citalopram, combined administration
        of citalopram and digoxin (single dose of 1 mg) did not significantly affect
        the pharmacokinetics of either citalopram or digoxin. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s72\"></a><a name=\"section-7.9\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.9 Lithium </h2>\n<p class=\"First\">Coadministration
        of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for
        5 days) had no significant effect on the pharmacokinetics of citalopram or
        lithium. Nevertheless, plasma lithium levels should be monitored with appropriate
        adjustment to the lithium dose in accordance with standard clinical practice.
        Because lithium may enhance the serotonergic effects of escitalopram, caution
        should be exercised when Lexapro and lithium are coadministered. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s73\"></a><a
        name=\"section-7.10\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>7.10
        Pimozide and Celexa </h2>\n<p class=\"First\">In a controlled study, a single
        dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given
        once daily for 11 days was associated with a mean increase in QTc values of
        approximately 10 msec compared to pimozide given alone. Racemic citalopram
        did not alter the mean AUC or C<span class=\"Sub\">max</span> of pimozide.
        The mechanism of this pharmacodynamic interaction is not known. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s74\"></a><a
        name=\"section-7.11\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>7.11
        Sumatriptan </h2>\n<p class=\"First\">There have been rare postmarketing reports
        describing patients with weakness, hyperreflexia, and incoordination following
        the use of an SSRI and sumatriptan. If concomitant treatment with sumatriptan
        and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram,
        escitalopram) is clinically warranted, appropriate observation of the patient
        is advised. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s75\"></a><a name=\"section-7.12\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.12 Theophylline </h2>\n<p class=\"First\">Combined
        administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2
        substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics
        of theophylline. The effect of theophylline on the pharmacokinetics of citalopram
        was not evaluated. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s76\"></a><a name=\"section-7.13\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.13 Warfarin </h2>\n<p class=\"First\">Administration
        of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics
        of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the
        clinical significance of which is unknown. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s77\"></a><a name=\"section-7.14\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.14 Carbamazepine </h2>\n<p class=\"First\">Combined
        administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine
        (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics
        of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels
        were unaffected, given the enzyme-inducing properties of carbamazepine, the
        possibility that carbamazepine might increase the clearance of escitalopram
        should be considered if the two drugs are coadministered. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s78\"></a><a
        name=\"section-7.15\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>7.15
        Triazolam </h2>\n<p class=\"First\">Combined administration of racemic citalopram
        (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single
        dose of 0.25 mg) did not significantly affect the pharmacokinetics of either
        citalopram or triazolam. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s79\"></a><a name=\"section-7.16\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.16 Ketoconazole </h2>\n<p class=\"First\">Combined
        administration of racemic citalopram (40 mg) and ketoconazole (200 mg), a
        potent CYP3A4 inhibitor, decreased the C<span class=\"Sub\">max</span> and
        AUC of ketoconazole by 21% and 10%, respectively, and did not significantly
        affect the pharmacokinetics of citalopram. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s80\"></a><a name=\"section-7.17\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.17 Ritonavir </h2>\n<p class=\"First\">Combined
        administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate
        and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect
        the pharmacokinetics of either ritonavir or escitalopram. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s81\"></a><a
        name=\"section-7.18\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>7.18
        CYP3A4 and -2C19 Inhibitors </h2>\n<p class=\"First\">\n<span class=\"Italics\">In
        vitro</span> studies indicated that CYP3A4 and -2C19 are the primary enzymes
        involved in the metabolism of escitalopram. However, coadministration of escitalopram
        (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly
        affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized
        by multiple enzyme systems, inhibition of a single enzyme may not appreciably
        decrease escitalopram clearance. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s82\"></a><a name=\"section-7.19\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.19 Drugs Metabolized by Cytochrome P4502D6 </h2>\n<p
        class=\"First\">\n<span class=\"Italics\">In vitro</span> studies did not
        reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady
        state levels of racemic citalopram were not significantly different in poor
        metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration
        of citalopram, suggesting that coadministration, with escitalopram, of a drug
        that inhibits CYP2D6, is unlikely to have clinically significant effects on
        escitalopram metabolism. However, there are limited <span class=\"Italics\">in
        vivo</span> data suggesting a modest CYP2D6 inhibitory effect for escitalopram,
        i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic
        antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6,
        resulted in a 40% increase in C<span class=\"Sub\">max</span> and a 100% increase
        in AUC of desipramine. The clinical significance of this finding is unknown.
        Nevertheless, caution is indicated in the coadministration of escitalopram
        and drugs metabolized by CYP2D6. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s83\"></a><a name=\"section-7.20\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.20 Metoprolol </h2>\n<p class=\"First\">Administration
        of 20 mg/day Lexapro for 21 days in healthy volunteers resulted in a 50% increase
        in C<span class=\"Sub\">max</span> and 82% increase in AUC of the beta-adrenergic
        blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol
        plasma levels have been associated with decreased cardioselectivity. Coadministration
        of Lexapro and metoprolol had no clinically significant effects on blood pressure
        or heart rate. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s84\"></a><a name=\"section-7.21\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>7.21 Electroconvulsive Therapy (ECT) </h2>\n<p class=\"First\">There
        are no clinical studies of the combined use of ECT and escitalopram. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"43684-0\">\n<a name=\"i4i_specific_populations_ID_s85\"></a><a
        name=\"section-8\"></a>\n<p></p>\n<h1>\n<a name=\"nlm43684-0\"></a>8 USE IN
        SPECIFIC POPULATIONS</h1>\n<div class=\"Section\" data-sectionCode=\"42228-7\">\n<a
        name=\"i4i_pregnancy_ID_s86\"></a><a name=\"section-8.1\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42228-7\"></a>8.1 Pregnancy</h2>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s87\"></a><a name=\"section-8.1.1\"></a>\n<p></p>\n<p
        class=\"First\">Pregnancy Category C </p>\n<p>In a rat embryo/fetal development
        study, oral administration of escitalopram (56, 112, or 150 mg/kg/day) to
        pregnant animals during the period of organogenesis resulted in decreased
        fetal body weight and associated delays in ossification at the two higher
        doses (approximately &ge; 56 times the maximum recommended human dose [MRHD]
        of 20 mg/day on a body surface area [mg/m<span class=\"Sup\">2</span>] basis).
        Maternal toxicity (clinical signs and decreased body weight gain and food
        consumption), mild at 56 mg/kg/day, was present at all dose levels. The developmental
        no-effect dose of 56 mg/kg/day is approximately 28 times the MRHD on a mg/m<span
        class=\"Sup\">2</span> basis. No teratogenicity was observed at any of the
        doses tested (as high as 75 times the MRHD on a mg/m<span class=\"Sup\">2</span>
        basis). </p>\n<p>When female rats were treated with escitalopram (6, 12, 24,
        or 48 mg/kg/day) during pregnancy and through weaning, slightly increased
        offspring mortality and growth retardation were noted at 48 mg/kg/day which
        is approximately 24 times the MRHD on a mg/m<span class=\"Sup\">2</span> basis.
        Slight maternal toxicity (clinical signs and decreased body weight gain and
        food consumption) was seen at this dose. Slightly increased offspring mortality
        was also seen at 24 mg/kg/day. The no-effect dose was 12 mg/kg/day which is
        approximately 6 times the MRHD on a mg/m<span class=\"Sup\">2</span> basis.
        </p>\n<p>In animal reproduction studies, racemic citalopram has been shown
        to have adverse effects on embryo/fetal and postnatal development, including
        teratogenic effects, when administered at doses greater than human therapeutic
        doses. </p>\n<p>In two rat embryo/fetal development studies, oral administration
        of racemic citalopram (32, 56, or 112 mg/kg/day) to pregnant animals during
        the period of organogenesis resulted in decreased embryo/fetal growth and
        survival and an increased incidence of fetal abnormalities (including cardiovascular
        and skeletal defects) at the high dose. This dose was also associated with
        maternal toxicity (clinical signs, decreased body weight gain). The developmental
        no-effect dose was 56 mg/kg/day. In a rabbit study, no adverse effects on
        embryo/fetal development were observed at doses of racemic citalopram of up
        to 16 mg/kg/day. Thus, teratogenic effects of racemic citalopram were observed
        at a maternally toxic dose in the rat and were not observed in the rabbit.
        </p>\n<p>When female rats were treated with racemic citalopram (4.8, 12.8,
        or 32 mg/kg/day) from late gestation through weaning, increased offspring
        mortality during the first 4 days after birth and persistent offspring growth
        retardation were observed at the highest dose. The no-effect dose was 12.8
        mg/kg/day. Similar effects on offspring mortality and growth were seen when
        dams were treated throughout gestation and early lactation at doses &ge; 24
        mg/kg/day. A no-effect dose was not determined in that study. </p>\n<p>There
        are no adequate and well-controlled studies in pregnant women; therefore,
        escitalopram should be used during pregnancy only if the potential benefit
        justifies the potential risk to the fetus. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"34078-6\">\n<a name=\"i4i_non_teratogenic_ID_s88\"></a><a
        name=\"section-8.1.2\"></a>\n<p></p>\n<p class=\"First\">Pregnancy-Nonteratogenic
        Effects </p>\n<p>Neonates exposed to Lexapro and other SSRIs or SNRIs, late
        in the third trimester, have developed complications requiring prolonged hospitalization,
        respiratory support, and tube feeding. Such complications can arise immediately
        upon delivery. Reported clinical findings have included respiratory distress,
        cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting,
        hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability,
        and constant crying. These features are consistent with either a direct toxic
        effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It
        should be noted that, in some cases, the clinical picture is consistent with
        serotonin syndrome [<span class=\"Italics\">see Warnings and Precautions (<a
        href=\"#i4i_section_ID_s28\">5.2</a>)</span>]. </p>\n<p>Infants exposed to
        SSRIs in late pregnancy may have an increased risk for persistent pulmonary
        hypertension of the newborn (PPHN). PPHN occurs in 1&mdash;2 per 1000 live
        births in the general population and is associated with substantial neonatal
        morbidity and mortality. In a retrospective, case-control study of 377 women
        whose infants were born with PPHN and 836 women whose infants were born healthy,
        the risk for developing PPHN was approximately six-fold higher for infants
        exposed to SSRIs after the 20th week of gestation compared to infants who
        had not been exposed to antidepressants during pregnancy. There is currently
        no corroborative evidence regarding the risk for PPHN following exposure to
        SSRIs in pregnancy; this is the first study that has investigated the potential
        risk. The study did not include enough cases with exposure to individual SSRIs
        to determine if all SSRIs posed similar levels of PPHN risk. </p>\n<p>When
        treating a pregnant woman with Lexapro during the third trimester, the physician
        should carefully consider both the potential risks and benefits of treatment
        [<span class=\"Italics\">see Dosage and Administration (<a href=\"#i4i_section_ID_s6\">2.1</a>)</span>].
        Physicians should note that in a prospective longitudinal study of 201 women
        with a history of major depression who were euthymic at the beginning of pregnancy,
        women who discontinued antidepressant medication during pregnancy were more
        likely to experience a relapse of major depression than women who continued
        antidepressant medication. </p>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"34079-4\">\n<a
        name=\"i4i_labour_delivery_ID_s89\"></a><a name=\"section-8.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm34079-4\"></a>8.2 Labor and Delivery</h2>\n<p class=\"First\">The
        effect of Lexapro on labor and delivery in humans is unknown. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"34080-2\">\n<a name=\"i4i_nursing_mothers_ID_s90\"></a><a
        name=\"section-8.3\"></a>\n<p></p>\n<h2>\n<a name=\"nlm34080-2\"></a>8.3 Nursing
        Mothers</h2>\n<p class=\"First\">Escitalopram is excreted in human breast
        milk. Limited data from women taking 10-20 mg escitalopram showed that exclusively
        breast-fed infants receive approximately 3.9% of the maternal weight-adjusted
        dose of escitalopram and 1.7% of the maternal weight-adjusted dose of desmethylcitalopram.
        There were two reports of infants experiencing excessive somnolence, decreased
        feeding, and weight loss in association with breastfeeding from a racemic
        citalopram-treated mother; in one case, the infant was reported to recover
        completely upon discontinuation of racemic citalopram by its mother and, in
        the second case, no follow-up information was available. Caution should be
        exercised and breastfeeding infants should be observed for adverse reactions
        when Lexapro is administered to a nursing woman. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"34081-0\">\n<a name=\"i4i_pediatric_use_ID_s91\"></a><a
        name=\"section-8.4\"></a>\n<p></p>\n<h2>\n<a name=\"nlm34081-0\"></a>8.4 Pediatric
        Use</h2>\n<p class=\"First\">Safety and effectiveness of Lexapro has not been
        established in pediatric patients (less than 12 years of age) with Major Depressive
        Disorder. Safety and effectiveness of Lexapro has been established in adolescents
        (12 to 17 years of age) for the treatment of major depressive disorder [<span
        class=\"Italics\">see Clinical Studies (<a href=\"#i4i_section_ID_s123\">14.1</a>)</span>].
        Although maintenance efficacy in adolescent patients with Major Depressive
        Disorder has not been systematically evaluated, maintenance efficacy can be
        extrapolated from adult data along with comparisons of escitalopram pharmacokinetic
        parameters in adults and adolescent patients. </p>\n<p>Safety and effectiveness
        of Lexapro has not been established in pediatric patients less than 18 years
        of age with Generalized Anxiety Disorder. </p>\n<p>Decrease appetite and weight
        loss have been observed in association with the use of SSRIs. Consequently,
        regular monitoring of weight and growth should be performed in children and
        adolescents treated with an SSRI such as Lexapro. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"34082-8\">\n<a name=\"i4i_geriatric_use_ID_s92\"></a><a
        name=\"section-8.5\"></a>\n<p></p>\n<h2>\n<a name=\"nlm34082-8\"></a>8.5 Geriatric
        Use</h2>\n<p class=\"First\">Approximately 6% of the 1144 patients receiving
        escitalopram in controlled trials of Lexapro in major depressive disorder
        and GAD were 60 years of age or older; elderly patients in these trials received
        daily doses of Lexapro between 10 and 20 mg. The number of elderly patients
        in these trials was insufficient to adequately assess for possible differential
        efficacy and safety measures on the basis of age. Nevertheless, greater sensitivity
        of some elderly individuals to effects of Lexapro cannot be ruled out. </p>\n<p>SSRIs
        and SNRIs, including Lexapro, have been associated with cases of clinically
        significant hyponatremia in elderly patients, who may be at greater risk for
        this adverse event [see <span class=\"Italics\">Hyponatremia (<a href=\"#i4i_section_ID_s32\">5.6</a>)</span>].
        </p>\n<p>In two pharmacokinetic studies, escitalopram half-life was increased
        by approximately 50% in elderly subjects as compared to young subjects and
        C<span class=\"Sub\">max</span> was unchanged [<span class=\"Italics\">see
        Clinical Pharmacology (<a href=\"#i4i_pharmacokinetics_ID_s103\">12.3</a>)</span>].
        10 mg/day is the recommended dose for elderly patients [<span class=\"Italics\">see
        Dosage and Administration (<a href=\"#i4i_section_ID_s15\">2.3</a>)</span>].
        </p>\n<p>Of 4422 patients in clinical studies of racemic citalopram, 1357
        were 60 and over, 1034 were 65 and over, and 457 were 75 and over. No overall
        differences in safety or effectiveness were observed between these subjects
        and younger subjects, and other reported clinical experience has not identified
        differences in responses between the elderly and younger patients, but again,
        greater sensitivity of some elderly individuals cannot be ruled out. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42227-9\">\n<a name=\"i4i_abuse_dependence_ID_s93\"></a><a
        name=\"section-9\"></a>\n<p></p>\n<h1>\n<a name=\"nlm42227-9\"></a>9 DRUG
        ABUSE AND DEPENDENCE</h1>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s94\"></a><a name=\"section-9.1\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>9.2 Abuse and Dependence </h2>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s95\"></a><a name=\"section-9.1.1\"></a>\n<p></p>\n<p
        class=\"First\">Physical and Psychological Dependence </p>\n<p>Animal studies
        suggest that the abuse liability of racemic citalopram is low. Lexapro has
        not been systematically studied in humans for its potential for abuse, tolerance,
        or physical dependence. The premarketing clinical experience with Lexapro
        did not reveal any drug-seeking behavior. However, these observations were
        not systematic and it is not possible to predict on the basis of this limited
        experience the extent to which a CNS-active drug will be misused, diverted,
        and/or abused once marketed. Consequently, physicians should carefully evaluate
        Lexapro patients for history of drug abuse and follow such patients closely,
        observing them for signs of misuse or abuse (e.g., development of tolerance,
        incrementations of dose, drug-seeking behavior). </p>\n</div>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"34088-5\">\n<a name=\"i4i_overdosage_ID_s96\"></a><a
        name=\"section-10\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34088-5\"></a>10 OVERDOSAGE</h1>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s97\"></a><a
        name=\"section-10.1\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>10.1
        Human Experience </h2>\n<p class=\"First\">In clinical trials of escitalopram,
        there were reports of escitalopram overdose, including overdoses of up to
        600 mg, with no associated fatalities. During the postmarketing evaluation
        of escitalopram, Lexapro overdoses involving overdoses of over 1000 mg have
        been reported. As with other SSRIs, a fatal outcome in a patient who has taken
        an overdose of escitalopram has been rarely reported. </p>\n<p>Symptoms most
        often accompanying escitalopram overdose, alone or in combination with other
        drugs and/or alcohol, included convulsions, coma, dizziness, hypotension,
        insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes
        (including QT prolongation and very rare cases of torsade de pointes). Acute
        renal failure has been very rarely reported accompanying overdose. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s98\"></a><a
        name=\"section-10.2\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>10.2
        Management of Overdose </h2>\n<p class=\"First\">Establish and maintain an
        airway to ensure adequate ventilation and oxygenation. Gastric evacuation
        by lavage and use of activated charcoal should be considered. Careful observation
        and cardiac and vital sign monitoring are recommended, along with general
        symptomatic and supportive care. Due to the large volume of distribution of
        escitalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion
        are unlikely to be of benefit. There are no specific antidotes for Lexapro.
        </p>\n<p>In managing overdosage, consider the possibility of multiple-drug
        involvement. The physician should consider contacting a poison control center
        for additional information on the treatment of any overdose. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"34089-3\">\n<a name=\"i4i_description_ID_s99\"></a><a
        name=\"section-11\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34089-3\"></a>11 DESCRIPTION</h1>\n<p
        class=\"First\">Lexapro&reg; (escitalopram oxalate) is an orally administered
        selective serotonin reuptake inhibitor (SSRI). Escitalopram is the pure S-enantiomer
        (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram
        oxalate is designated S-(+)-1-[3-(dimethyl-amino)propyl]-1-(<span class=\"Italics\">p</span>-fluorophenyl)-5-phthalancarbonitrile
        oxalate with the following structural formula: </p>\n<div class=\"Figure\">\n<img
        src=\"image.cfm?id=104317&type=img&name=02194826%2D72a8%2D4436%2D9ade%2De36fa5bb99da%2D01.jpg\"
        alt=\"Structural Formula \"></div>\n<p>The molecular formula is C<span class=\"Sub\">20</span>H<span
        class=\"Sub\">21</span>FN<span class=\"Sub\">2O</span> &bull; C<span class=\"Sub\">2</span>H<span
        class=\"Sub\">2</span>O<span class=\"Sub\">4</span> and the molecular weight
        is 414.40. </p>\n<p>Escitalopram oxalate occurs as a fine, white to slightly-yellow
        powder and is freely soluble in methanol and dimethyl sulfoxide (DMSO), soluble
        in isotonic saline solution, sparingly soluble in water and ethanol, slightly
        soluble in ethyl acetate, and insoluble in heptane. </p>\n<p>Lexapro (escitalopram
        oxalate) is available as tablets or as an oral solution. </p>\n<p>Lexapro
        tablets are film-coated, round tablets containing escitalopram oxalate in
        strengths equivalent to 5 mg, 10 mg, and 20 mg escitalopram base. The 10 and
        20 mg tablets are scored. The tablets also contain the following inactive
        ingredients: talc, croscarmellose sodium, microcrystalline cellulose/colloidal
        silicon dioxide, and magnesium stearate. The film coating contains hypromellose,
        titanium dioxide, and polyethylene glycol. </p>\n<p>Lexapro oral solution
        contains escitalopram oxalate equivalent to 1 mg/mL escitalopram base. It
        also contains the following inactive ingredients: sorbitol, purified water,
        citric acid, sodium citrate, malic acid, glycerin, propylene glycol, methylparaben,
        propylparaben, and natural peppermint flavor. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"34090-1\">\n<a name=\"i4i_clinical_pharmacology_ID_s100\"></a><a
        name=\"section-12\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34090-1\"></a>12 CLINICAL
        PHARMACOLOGY</h1>\n<div class=\"Section\" data-sectionCode=\"43679-0\">\n<a
        name=\"i4i_mechanism_action_ID_s101\"></a><a name=\"section-12.1\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm43679-0\"></a>12.1 Mechanism of Action</h2>\n<p class=\"First\">The
        mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic
        citalopram, is presumed to be linked to potentiation of serotonergic activity
        in the central nervous system (CNS) resulting from its inhibition of CNS neuronal
        reuptake of serotonin (5-HT). </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"43681-6\">\n<a
        name=\"i4i_pharmacodynamics_ID_s102\"></a><a name=\"section-12.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm43681-6\"></a>12.2 Pharmacodynamics</h2>\n<p class=\"First\">\n<span
        class=\"Italics\">In vitro</span> and <span class=\"Italics\">in vivo</span>
        studies in animals suggest that escitalopram is a highly selective serotonin
        reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine
        neuronal reuptake. Escitalopram is at least 100-fold more potent than the
        R-enantiomer with respect to inhibition of 5-HT reuptake and inhibition of
        5-HT neuronal firing rate. Tolerance to a model of antidepressant effect in
        rats was not induced by long-term (up to 5 weeks) treatment with escitalopram.
        Escitalopram has no or very low affinity for serotonergic (5-HT<span class=\"Sub\">1-7</span>)
        or other receptors including alpha- and beta-adrenergic, dopamine (D<span
        class=\"Sub\">1-5</span>), histamine (H<span class=\"Sub\">1-3</span>), muscarinic
        (M<span class=\"Sub\">1-5</span>), and benzodiazepine receptors. Escitalopram
        also does not bind to, or has low affinity for, various ion channels including
        Na<span class=\"Sup\">+</span>, K<span class=\"Sup\">+</span>, Cl<span class=\"Sup\">-</span>,
        and Ca<span class=\"Sup\">++</span> channels. Antagonism of muscarinic, histaminergic,
        and adrenergic receptors has been hypothesized to be associated with various
        anticholinergic, sedative, and cardiovascular side effects of other psychotropic
        drugs. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"43682-4\">\n<a
        name=\"i4i_pharmacokinetics_ID_s103\"></a><a name=\"section-12.3\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm43682-4\"></a>12.3 Pharmacokinetics</h2>\n<p class=\"First\">The
        single- and multiple-dose pharmacokinetics of escitalopram are linear and
        dose-proportional in a dose range of 10 to 30 mg/day. Biotransformation of
        escitalopram is mainly hepatic, with a mean terminal half-life of about 27-32
        hours. With once-daily dosing, steady state plasma concentrations are achieved
        within approximately one week. At steady state, the extent of accumulation
        of escitalopram in plasma in young healthy subjects was 2.2-2.5 times the
        plasma concentrations observed after a single dose. The tablet and the oral
        solution dosage forms of escitalopram oxalate are bioequivalent. </p>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s104\"></a><a
        name=\"section-12.3.1\"></a>\n<p></p>\n<p class=\"First\">Absorption and Distribution
        </p>\n<p>Following a single oral dose (20 mg tablet or solution) of escitalopram,
        peak blood levels occur at about 5 hours. Absorption of escitalopram is not
        affected by food. </p>\n<p>The absolute bioavailability of citalopram is about
        80% relative to an intravenous dose, and the volume of distribution of citalopram
        is about 12 L/kg. Data specific on escitalopram are unavailable. </p>\n<p>The
        binding of escitalopram to human plasma proteins is approximately 56%. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s105\"></a><a
        name=\"section-12.3.2\"></a>\n<p></p>\n<p class=\"First\">Metabolism and Elimination
        </p>\n<p>Following oral administrations of escitalopram, the fraction of drug
        recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is
        about 8% and 10%, respectively. The oral clearance of escitalopram is 600
        mL/min, with approximately 7% of that due to renal clearance. </p>\n<p>Escitalopram
        is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT). In humans, unchanged
        escitalopram is the predominant compound in plasma. At steady state, the concentration
        of the escitalopram metabolite S-DCT in plasma is approximately one-third
        that of escitalopram. The level of S-DDCT was not detectable in most subjects.
        <span class=\"Italics\">In vitro</span> studies show that escitalopram is
        at least 7 and 27 times more potent than S-DCT and S-DDCT, respectively, in
        the inhibition of serotonin reuptake, suggesting that the metabolites of escitalopram
        do not contribute significantly to the antidepressant actions of escitalopram.
        S-DCT and S-DDCT also have no or very low affinity for serotonergic (5-HT<span
        class=\"Sub\">1-7</span>) or other receptors including alpha- and beta-adrenergic,
        dopamine (D<span class=\"Sub\">1-5</span>), histamine (H<span class=\"Sub\">1-3</span>),
        muscarinic (M<span class=\"Sub\">1-5</span>), and benzodiazepine receptors.
        S-DCT and S-DDCT also do not bind to various ion channels including Na<span
        class=\"Sup\">+</span>, K<span class=\"Sup\">+</span>, Cl<span class=\"Sup\">-</span>,
        and Ca<span class=\"Sup\">++</span> channels. </p>\n<p>\n<span class=\"Italics\">In
        vitro</span> studies using human liver microsomes indicated that CYP3A4 and
        CYP2C19 are the primary isozymes involved in the N-demethylation of escitalopram.
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s106\"></a><a
        name=\"section-12.3.3\"></a>\n<p></p>\n<p class=\"First\">Population Subgroups
        </p>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s107\"></a><a
        name=\"section-12.3.3.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Underline\">Age</span>\n</p>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s108\"></a><a
        name=\"section-12.3.3.1.1\"></a>\n<p></p>\n<p class=\"First\">Adolescents
        - In a single dose study of 10 mg escitalopram, AUC of escitalopram decreased
        by 19%, and C<span class=\"Sub\">max</span> increased by 26% in healthy adolescent
        subjects (12 to 17 years of age) compared to adults. Following multiple dosing
        of 40 mg/day citalopram, escitalopram elimination half-life, steady-state
        C<span class=\"Sub\">max</span> and AUC were similar in patients with MDD
        (12 to 17 years of age) compared to adult patients. No adjustment of dosage
        is needed in adolescent patients. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s109\"></a><a name=\"section-12.3.3.1.2\"></a>\n<p></p>\n<p
        class=\"First\">Elderly - Escitalopram pharmacokinetics in subjects &ge; 65
        years of age were compared to younger subjects in a single-dose and a multiple-dose
        study. Escitalopram AUC and half-life were increased by approximately 50%
        in elderly subjects, and C<span class=\"Sub\">max</span> was unchanged. 10
        mg is the recommended dose for elderly patients [<span class=\"Italics\">see
        Dosage and Administration (<a href=\"#i4i_section_ID_s15\">2.3</a>)</span>].
        </p>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s110\"></a><a name=\"section-12.3.3.2\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Underline\">Gender</span> - Based on data
        from single- and multiple-dose studies measuring escitalopram in elderly,
        young adults, and adolescents, no dosage adjustment on the basis of gender
        is needed. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s111\"></a><a name=\"section-12.3.3.3\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Underline\">Reduced hepatic function</span>
        - Citalopram oral clearance was reduced by 37% and half-life was doubled in
        patients with reduced hepatic function compared to normal subjects. 10 mg
        is the recommended dose of escitalopram for most hepatically impaired patients
        [<span class=\"Italics\">see Dosage and Administration (<a href=\"#i4i_section_ID_s15\">2.3</a>)</span>].
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s112\"></a><a
        name=\"section-12.3.3.4\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Underline\">Reduced
        renal function</span> - In patients with mild to moderate renal function impairment,
        oral clearance of citalopram was reduced by 17% compared to normal subjects.
        No adjustment of dosage for such patients is recommended. No information is
        available about the pharmacokinetics of escitalopram in patients with severely
        reduced renal function (creatinine clearance &lt; 20 mL/min). </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s113\"></a><a
        name=\"section-12.3.3.5\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Underline\">Drug-Drug
        Interactions</span>\n</p>\n<p>\n<span class=\"Italics\">In vitro</span> enzyme
        inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4,
        -1A2, -2C9, -2C19, and -2E1. Based on <span class=\"Italics\">in vitro</span>
        data, escitalopram would be expected to have little inhibitory effect on <span
        class=\"Italics\">in vivo</span> metabolism mediated by these cytochromes.
        While <span class=\"Italics\">in vivo</span> data to address this question
        are limited, results from drug interaction studies suggest that escitalopram,
        at a dose of 20 mg, has no 3A4 inhibitory effect and a modest 2D6 inhibitory
        effect. See <span class=\"Italics\">Drug Interactions (<a href=\"#i4i_section_ID_s81\">7.18</a>)</span>
        for more detailed information on available drug interaction data. </p>\n</div>\n</div>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"43680-8\">\n<a name=\"i4i_nonclinical_toxicology_ID_s114\"></a><a
        name=\"section-13\"></a>\n<p></p>\n<h1>\n<a name=\"nlm43680-8\"></a>13 NONCLINICAL
        TOXICOLOGY</h1>\n<div class=\"Section\" data-sectionCode=\"34083-6\">\n<a
        name=\"i4i_carcinogenesis_mutagenesis_fertility_ID_s115\"></a><a name=\"section-13.1\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm34083-6\"></a>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s116\"></a><a
        name=\"section-13.1.1\"></a>\n<p></p>\n<p class=\"First\">Carcinogenesis </p>\n<p>Racemic
        citalopram was administered in the diet to NMRI/BOM strain mice and COBS WI
        strain rats for 18 and 24 months, respectively. There was no evidence for
        carcinogenicity of racemic citalopram in mice receiving up to 240 mg/kg/day.
        There was an increased incidence of small intestine carcinoma in rats receiving
        8 or 24 mg/kg/day racemic citalopram. A no-effect dose for this finding was
        not established. The relevance of these findings to humans is unknown. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s117\"></a><a
        name=\"section-13.1.2\"></a>\n<p></p>\n<p class=\"First\">Mutagenesis </p>\n<p>Racemic
        citalopram was mutagenic in the <span class=\"Italics\">in vitro</span> bacterial
        reverse mutation assay (Ames test) in 2 of 5 bacterial strains (Salmonella
        TA98 and TA1537) in the absence of metabolic activation. It was clastogenic
        in the <span class=\"Italics\">in vitro</span> Chinese hamster lung cell assay
        for chromosomal aberrations in the presence and absence of metabolic activation.
        Racemic citalopram was not mutagenic in the <span class=\"Italics\">in vitro</span>
        mammalian forward gene mutation assay (HPRT) in mouse lymphoma cells or in
        a coupled <span class=\"Italics\">in vitro/in vivo</span> unscheduled DNA
        synthesis (UDS) assay in rat liver. It was not clastogenic in the <span class=\"Italics\">in
        vitro</span> chromosomal aberration assay in human lymphocytes or in two <span
        class=\"Italics\">in vivo</span> mouse micronucleus assays. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s118\"></a><a
        name=\"section-13.1.3\"></a>\n<p></p>\n<p class=\"First\">Impairment of Fertility
        </p>\n<p>When racemic citalopram was administered orally to 16 male and 24
        female rats prior to and throughout mating and gestation at doses of 32, 48,
        and 72 mg/kg/day, mating was decreased at all doses, and fertility was decreased
        at doses &ge; 32 mg/kg/day. Gestation duration was increased at 48 mg/kg/day.
        </p>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"34091-9\">\n<a
        name=\"i4i_animal_pharmacology_ID_s119\"></a><a name=\"section-13.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm34091-9\"></a>13.2 Animal Toxicology and/or Pharmacology</h2>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s120\"></a><a
        name=\"section-13.2.1\"></a>\n<p></p>\n<p class=\"First\">Retinal Changes
        in Rats </p>\n<p>Pathologic changes (degeneration/atrophy) were observed in
        the retinas of albino rats in the 2-year carcinogenicity study with racemic
        citalopram. There was an increase in both incidence and severity of retinal
        pathology in both male and female rats receiving 80 mg/kg/day. Similar findings
        were not present in rats receiving 24 mg/kg/day of racemic citalopram for
        two years, in mice receiving up to 240 mg/kg/day of racemic citalopram for
        18 months, or in dogs receiving up to 20 mg/kg/day of racemic citalopram for
        one year. </p>\n<p>Additional studies to investigate the mechanism for this
        pathology have not been performed, and the potential significance of this
        effect in humans has not been established. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s121\"></a><a name=\"section-13.2.2\"></a>\n<p></p>\n<p
        class=\"First\">Cardiovascular Changes in Dogs </p>\n<p>In a one-year toxicology
        study, 5 of 10 beagle dogs receiving oral racemic citalopram doses of 8 mg/kg/day
        died suddenly between weeks 17 and 31 following initiation of treatment. Sudden
        deaths were not observed in rats at doses of racemic citalopram up to 120
        mg/kg/day, which produced plasma levels of citalopram and its metabolites
        demethylcitalopram and didemethylcitalopram (DDCT) similar to those observed
        in dogs at 8 mg/kg/day. A subsequent intravenous dosing study demonstrated
        that in beagle dogs, racemic DDCT caused QT prolongation, a known risk factor
        for the observed outcome in dogs. </p>\n</div>\n</div>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"34092-7\">\n<a name=\"i4i_clinical_studies_ID_s122\"></a><a
        name=\"section-14\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34092-7\"></a>14 CLINICAL
        STUDIES</h1>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s123\"></a><a
        name=\"section-14.1\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>14.1
        Major Depressive Disorder </h2>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s124\"></a><a name=\"section-14.1.1\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Adolescents</span>\n</p>\n<p>The efficacy
        of Lexapro as an acute treatment for major depressive disorder in adolescent
        patients was established in an 8-week, flexible-dose, placebo-controlled study
        that compared Lexapro 10-20 mg/day to placebo in outpatients 12 to 17 years
        of age inclusive who met DSM-IV criteria for major depressive disorder. The
        primary outcome was change from baseline to endpoint in the Children's Depression
        Rating Scale - Revised (CDRS-R). In this study, Lexapro showed statistically
        significant greater mean improvement compared to placebo on the CDRS-R. </p>\n<p>The
        efficacy of Lexapro in the acute treatment of major depressive disorder in
        adolescents was established, in part, on the basis of extrapolation from the
        8-week, flexible-dose, placebo-controlled study with racemic citalopram 20-40
        mg/day. In this outpatient study in children and adolescents 7 to 17 years
        of age who met DSM-IV criteria for major depressive disorder, citalopram treatment
        showed statistically significant greater mean improvement from baseline, compared
        to placebo, on the CDRS-R; the positive results for this trial largely came
        from the adolescent subgroup. </p>\n<p>Two additional flexible-dose, placebo-controlled
        MDD studies (one Lexapro study in patients ages 7 to 17 and one citalopram
        study in adolescents) did not demonstrate efficacy. </p>\n<p>Although maintenance
        efficacy in adolescent patients has not been systematically evaluated, maintenance
        efficacy can be extrapolated from adult data along with comparisons of escitalopram
        pharmacokinetic parameters in adults and adolescent patients. </p>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s125\"></a><a
        name=\"section-14.1.2\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Adults</span>\n</p>\n<p>The
        efficacy of Lexapro as a treatment for major depressive disorder was established
        in three, 8-week, placebo-controlled studies conducted in outpatients between
        18 and 65 years of age who met DSM-IV criteria for major depressive disorder.
        The primary outcome in all three studies was change from baseline to endpoint
        in the Montgomery Asberg Depression Rating Scale (MADRS). </p>\n<p>A fixed-dose
        study compared 10 mg/day Lexapro and 20 mg/day Lexapro to placebo and 40 mg/day
        citalopram. The 10 mg/day and 20 mg/day Lexapro treatment groups showed statistically
        significant greater mean improvement compared to placebo on the MADRS. The
        10 mg and 20 mg Lexapro groups were similar on this outcome measure. </p>\n<p>In
        a second fixed-dose study of 10 mg/day Lexapro and placebo, the 10 mg/day
        Lexapro treatment group showed statistically significant greater mean improvement
        compared to placebo on the MADRS. </p>\n<p>In a flexible-dose study, comparing
        Lexapro, titrated between 10 and 20 mg/day, to placebo and citalopram, titrated
        between 20 and 40 mg/day, the Lexapro treatment group showed statistically
        significant greater mean improvement compared to placebo on the MADRS. </p>\n<p>Analyses
        of the relationship between treatment outcome and age, gender, and race did
        not suggest any differential responsiveness on the basis of these patient
        characteristics. </p>\n<p>In a longer-term trial, 274 patients meeting (DSM-IV)
        criteria for major depressive disorder, who had responded during an initial
        8-week, open-label treatment phase with Lexapro 10 or 20 mg/day, were randomized
        to continuation of Lexapro at their same dose, or to placebo, for up to 36
        weeks of observation for relapse. Response during the open-label phase was
        defined by having a decrease of the MADRS total score to &le; 12. Relapse
        during the double-blind phase was defined as an increase of the MADRS total
        score to &ge; 22, or discontinuation due to insufficient clinical response.
        Patients receiving continued Lexapro experienced a statistically significant
        longer time to relapse compared to those receiving placebo. </p>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s126\"></a><a
        name=\"section-14.2\"></a>\n<p></p>\n<h2>\n<a name=\"nlm42229-5\"></a>14.2
        Generalized Anxiety Disorder </h2>\n<p class=\"First\">The efficacy of Lexapro
        in the acute treatment of Generalized Anxiety Disorder (GAD) was demonstrated
        in three, 8-week, multicenter, flexible-dose, placebo-controlled studies that
        compared Lexapro 10-20 mg/day to placebo in adult outpatients between 18 and
        80 years of age who met DSM-IV criteria for GAD. In all three studies, Lexapro
        showed statistically significant greater mean improvement compared to placebo
        on the Hamilton Anxiety Scale (HAM-A). </p>\n<p>There were too few patients
        in differing ethnic and age groups to adequately assess whether or not Lexapro
        has differential effects in these groups. There was no difference in response
        to Lexapro between men and women. </p>\n</div>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"34069-5\">\n<a name=\"i4i_how_supplied_ID_s127\"></a><a
        name=\"section-15\"></a>\n<p></p>\n<h1>\n<a name=\"nlm34069-5\"></a>16 HOW
        SUPPLIED/STORAGE AND HANDLING</h1>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s128\"></a><a name=\"section-15.1\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>16.1 Tablets </h2>\n<p class=\"First\">5 mg Tablets:<br>Bottle
        of 100&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
        &nbsp;NDC # 0456-2005-01 </p>\n<p>White to off-white, round, non-scored, film-coated.
        Imprint \"FL\" on one side of the tablet and \"5\" on the other side. </p>\n<p>10
        mg Tablets:<br>Bottle of 100&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
        &nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-2010-01<br>10 x 10 Unit Dose&nbsp; &nbsp;
        &nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-2010-63 </p>\n<p>White to off-white,
        round, scored, film-coated. Imprint on scored side with \"F\" on the left
        side and \"L\" on the right side. Imprint on the non-scored side with \"10\".
        </p>\n<p>20 mg Tablets:<br>Bottle of 100&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
        &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-2020-01<br>10 x 10 Unit
        Dose&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-2020-63 </p>\n<p>White
        to off-white, round, scored, film-coated. Imprint on scored side with \"F\"
        on the left side and \"L\" on the right side. Imprint on the non-scored side
        with \"20\". </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s129\"></a><a name=\"section-15.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>16.2 Oral Solution </h2>\n<p class=\"First\">5 mg/5
        mL, peppermint flavor (240 mL) NDC # 0456-2101-08 </p>\n<div class=\"Section\"
        data-sectionCode=\"44425-7\">\n<a name=\"i4i_storage_ID_s130\"></a><a name=\"section-15.2.1\"></a>\n<p></p>\n<p
        class=\"First\">Storage and Handling </p>\n<p>Store at 25&deg;C (77&deg;F);
        excursions permitted to 15 - 30&deg;C (59-86&deg;F). </p>\n</div>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s131\"></a><a
        name=\"section-16\"></a>\n<p></p>\n<h1>\n<a name=\"nlm42229-5\"></a>17 PATIENT
        COUNSELING INFORMATION </h1>\n<p class=\"First\">See FDA-approved Medication
        Guide </p>\n<div class=\"Section\" data-sectionCode=\"34076-0\">\n<a name=\"i4i_info_patients_duplicate_ID_s132\"></a><a
        name=\"section-16.1\"></a>\n<p></p>\n<h2>\n<a name=\"nlm34076-0\"></a>17.1
        Information for Patients </h2>\n<p class=\"First\">Physicians are advised
        to discuss the following issues with patients for whom they prescribe Lexapro.
        </p>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s133\"></a><a
        name=\"section-16.1.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">General
        Information about Medication Guide</span>\n</p>\n<p>Prescribers or other health
        professionals should inform patients, their families, and their caregivers
        about the benefits and risks associated with treatment with Lexapro and should
        counsel them in its appropriate use. A patient Medication Guide about &ldquo;Antidepressant
        Medicines, Depression and other Serious Mental Illness, and Suicidal Thoughts
        or Actions&rdquo; is available for Lexapro. The prescriber or health professional
        should instruct patients, their families, and their caregivers to read the
        Medication Guide and should assist them in understanding its contents. Patients
        should be given the opportunity to discuss the contents of the Medication
        Guide and to obtain answers to any questions they may have. The complete text
        of the Medication Guide is reprinted at the end of this document. </p>\n<p>Patients
        should be advised of the following issues and asked to alert their prescriber
        if these occur while taking Lexapro. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s134\"></a><a name=\"section-16.1.2\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Clinical Worsening and Suicide Risk</span>\n</p>\n<p>Patients,
        their families, and their caregivers should be encouraged to be alert to the
        emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility,
        aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania,
        mania, other unusual changes in behavior, worsening of depression, and suicidal
        ideation, especially early during antidepressant treatment and when the dose
        is adjusted up or down. Families and caregivers of patients should be advised
        to look for the emergence of such symptoms on a day-to-day basis, since changes
        may be abrupt. Such symptoms should be reported to the patient's prescriber
        or health professional, especially if they are severe, abrupt in onset, or
        were not part of the patient's presenting symptoms. Symptoms such as these
        may be associated with an increased risk for suicidal thinking and behavior
        and indicate a need for very close monitoring and possibly changes in the
        medication [<span class=\"Italics\">see Warnings and Precautions (<a href=\"#i4i_section_ID_s26\">5.1</a>)</span>].
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s135\"></a><a
        name=\"section-16.1.3\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Serotonin
        Syndrome</span>\n</p>\n<p>Patients should be cautioned about the risk of serotonin
        syndrome with the concomitant use of <span class=\"Bold\">Lexapro</span> and
        triptans, tramadol or other serotonergic agents [<span class=\"Italics\">see
        Warnings and Precautions (<a href=\"#i4i_section_ID_s28\">5.2</a>)</span>].
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s136\"></a><a
        name=\"section-16.1.4\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Abnormal
        Bleeding</span>\n</p>\n<p>Patients should be cautioned about the concomitant
        use of Lexapro and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation
        since combined use of psychotropic drugs that interfere with serotonin reuptake
        and these agents has been associated with an increased risk of bleeding [<span
        class=\"Italics\">see Warnings and Precautions (<a href=\"#i4i_section_ID_s33\">5.7</a>)</span>].
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s137\"></a><a
        name=\"section-16.1.5\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Concomitant
        Medications</span>\n</p>\n<p>Since escitalopram is the active isomer of racemic
        citalopram (Celexa), the two agents should not be coadministered. Patients
        should be advised to inform their physician if they are taking, or plan to
        take, any prescription or over-the-counter drugs, as there is a potential
        for interactions. </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a
        name=\"i4i_section_ID_s138\"></a><a name=\"section-16.1.6\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Continuing the Therapy Prescribed</span>\n</p>\n<p>While
        patients may notice improvement with Lexapro therapy in 1 to 4 weeks, they
        should be advised to continue therapy as directed. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s139\"></a><a name=\"section-16.1.7\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Interference with Psychomotor Performance</span>\n</p>\n<p>Because
        psychoactive drugs may impair judgment, thinking, or motor skills, patients
        should be cautioned about operating hazardous machinery, including automobiles,
        until they are reasonably certain that Lexapro therapy does not affect their
        ability to engage in such activities. </p>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s140\"></a><a name=\"section-16.1.8\"></a>\n<p></p>\n<p
        class=\"First\">\n<span class=\"Bold\">Alcohol</span>\n</p>\n<p>Patients should
        be told that, although Lexapro has not been shown in experiments with normal
        subjects to increase the mental and motor skill impairments caused by alcohol,
        the concomitant use of Lexapro and alcohol in depressed patients is not advised.
        </p>\n</div>\n<div class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s141\"></a><a
        name=\"section-16.1.9\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Pregnancy
        and Breast Feeding</span>\n</p>\n<p>Patients should be advised to notify their
        physician if they </p>\n<ul>\n<li>become pregnant or intend to become pregnant
        during therapy. </li>\n<li>are breastfeeding an infant. </li>\n</ul>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s142\"></a><a
        name=\"section-16.1.10\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Need
        for Comprehensive Treatment Program</span>\n</p>\n<p>Lexapro is indicated
        as an integral part of a total treatment program for MDD that may include
        other measures (psychological, educational, social) for patients with this
        syndrome. Drug treatment may not be indicated for all adolescents with this
        syndrome. Safety and effectiveness of Lexapro in MDD has not been established
        in pediatrics patients less than 12 years of age. Antidepressants are not
        intended for use in the adolescent who exhibits symptoms secondary to environmental
        factors and/or other primary psychiatric disorders. Appropriate educational
        placement is essential and psychosocial intervention is often helpful. When
        remedial measures alone are insufficient, the decision to prescribe antidepressant
        medication will depend upon the physician's assessment of the chronicity and
        severity of the patient's symptoms. </p>\n</div>\n</div>\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"i4i_section_ID_s143\"></a><a name=\"section-16.2\"></a>\n<p></p>\n<h2>\n<a
        name=\"nlm42229-5\"></a>17.2 FDA-Approved Medication Guide </h2>\n</div>\n</div>\n<div
        class=\"Section\" data-sectionCode=\"42231-1\">\n<a name=\"i4i_medguide_ID_s144\"></a><a
        name=\"section-17\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">Medication
        Guide</span>\n</p>\n<p>Lexapro (leks-a-pro) <br>(escitalopram oxalate) <br>Tablets/Oral
        Solution </p>\n<p>Read the Medication Guide that comes with Lexapro before
        you start taking it and each time you get a refill. There may be new information.
        This Medication Guide does not take the place of talking to your healthcare
        provider about your medical condition or treatment. Talk with your healthcare
        provider if there is something you do not understand or want to learn more
        about. </p>\n<p>\n<span class=\"Bold\">What is the most important information
        I should know about Lexapro?</span>\n</p>\n<p>Lexapro and other antidepressant
        medicines may cause serious side effects, including: </p>\n<p>\n<span class=\"Bold\">1.
        Suicidal thoughts or actions:</span>\n</p>\n<ul>\n<li>\n<span class=\"Bold\">Lexapro
        and other antidepressant medicines may increase suicidal thoughts or actions</span>
        in some children, teenagers, or young adults within the <span class=\"Bold\">first
        few months of treatment or when the dose is changed.</span>\n</li>\n<li>Depression
        or other serious mental illnesses are the most important causes of suicidal
        thoughts or actions. </li>\n<li>Watch for these changes and call your healthcare
        provider right away if you notice:<ul>\n<li>New or sudden changes in mood,
        behavior, actions, thoughts, or feelings, especially if severe. </li>\n<li>Pay
        particular attention to such changes when Lexapro is started or when the dose
        is changed. </li>\n</ul>\n</li>\n</ul>\n<p>Keep all follow-up visits with
        your healthcare provider and call between visits if you are worried about
        symptoms. </p>\n<p>\n<span class=\"Bold\">Call your healthcare provider right
        away if you have any of the following symptoms, or call 911 if an emergency,
        especially if they are new, worse, or worry you:</span>\n</p>\n<ul>\n<li>attempts
        to commit suicide </li>\n<li>acting on dangerous impulses </li>\n<li>acting
        aggressive or violent </li>\n<li>thoughts about suicide or dying </li>\n<li>new
        or worse depression </li>\n<li>new or worse anxiety or panic attacks </li>\n<li>feeling
        agitated, restless, angry or irritable </li>\n<li>trouble sleeping </li>\n<li>an
        increase in activity or talking more than what is normal for you </li>\n<li>other
        unusual changes in behavior or mood </li>\n</ul>\n<p>\n<span class=\"Bold\">Call
        your healthcare provider right away if you have any of the following symptoms,
        or call 911 if an emergency. Lexapro may be associated with these serious
        side effects:</span>\n</p>\n<p>\n<span class=\"Bold\">2. Serotonin Syndrome
        or Neuroleptic Malignant Syndrome-like reactions. This condition can be life-threatening
        and may include:</span>\n</p>\n<ul>\n<li>agitation, hallucinations, coma or
        other changes in mental status </li>\n<li>coordination problems or muscle
        twitching (overactive reflexes) </li>\n<li>racing heartbeat, high or low blood
        pressure </li>\n<li>sweating or fever </li>\n<li>nausea, vomiting, or diarrhea
        </li>\n<li>muscle rigidity </li>\n</ul>\n<p>\n<span class=\"Bold\">3. Severe
        allergic reactions:</span>\n</p>\n<ul>\n<li>trouble breathing </li>\n<li>swelling
        of the face, tongue, eyes or mouth </li>\n<li>rash, itchy welts (hives) or
        blisters, alone or with fever or joint pain </li>\n</ul>\n<p>\n<span class=\"Bold\">4.
        Abnormal bleeding</span>: Lexapro and other antidepressant medicines may increase
        your risk of bleeding or bruising, especially if you take the blood thinner
        warfarin (Coumadin<span class=\"Sup\">&reg;</span>, Jantoven<span class=\"Sup\">&reg;</span>),
        a non-steroidal anti-inflammatory drug (NSAIDs, like ibuprofen or naproxen),
        or aspirin. </p>\n<p>\n<span class=\"Bold\">5. Seizures or convulsions</span>\n</p>\n<p>\n<span
        class=\"Bold\">6. Manic episodes:</span>\n</p>\n<ul>\n<li>greatly increased
        energy </li>\n<li>severe trouble sleeping </li>\n<li>racing thoughts </li>\n<li>reckless
        behavior </li>\n<li>unusually grand ideas </li>\n<li>excessive happiness or
        irritability </li>\n<li>talking more or faster than usual </li>\n</ul>\n<p>\n<span
        class=\"Bold\">7. Changes in appetite or weight.</span> Children and adolescents
        should have height and weight monitored during treatment. </p>\n<p>\n<span
        class=\"Bold\">8. Low salt (sodium) levels in the blood.</span> Elderly people
        may be at greater risk for this. Symptoms may include: </p>\n<ul>\n<li>headache
        </li>\n<li>weakness or feeling unsteady </li>\n<li>confusion, problems concentrating
        or thinking or memory problems </li>\n</ul>\n<p>\n<span class=\"Bold\">Do
        not stop Lexapro without first talking to your healthcare provider</span>.
        Stopping Lexapro too quickly may cause serious symptoms including: </p>\n<ul>\n<li>anxiety,
        irritability, high or low mood, feeling restless or changes in sleep habits
        </li>\n<li>headache, sweating, nausea, dizziness </li>\n<li>electric shock-like
        sensations, shaking, confusion </li>\n</ul>\n<p>\n<span class=\"Bold\">What
        is Lexapro?</span>\n</p>\n<p>Lexapro is a prescription medicine used to treat
        depression. It is important to talk with your healthcare provider about the
        risks of treating depression and also the risks of not treating it. You should
        discuss all treatment choices with your healthcare provider. Lexapro is <span
        class=\"Underline\">also</span> used to treat: </p>\n<ul>\n<li>Major Depressive
        Disorder (MDD) </li>\n<li>Generalized Anxiety Disorder (GAD) </li>\n</ul>\n<p>Talk
        to your healthcare provider if you do not think that your condition is getting
        better with Lexapro treatment. </p>\n<p>\n<span class=\"Bold\">Who should
        not take Lexapro?</span>\n</p>\n<p>Do not take Lexapro if you: </p>\n<ul>\n<li>are
        allergic to escitalopram oxalate or citalopram hydrobromide or any of the
        ingredients in Lexapro. See the end of this Medication Guide for a complete
        list of ingredients in Lexapro. </li>\n<li>take a Monoamine Oxidase Inhibitor
        (MAOI). Ask your healthcare provider or pharmacist if you are not sure if
        you take an MAOI, including the antibiotic linezolid.<ul>\n<li>Do not take
        an MAOI within 14 days of stopping Lexapro. </li>\n<li>Do not start Lexapro
        if you stopped taking an MAOI in the last 14 days. </li>\n</ul>\n<p class=\"First\">\n<br>\n<span
        class=\"Bold\">People who take Lexapro close in time to an MAOI may have serious
        or even life-threatening side effects. Get medical help right away if you
        have any of these symptoms:</span>\n</p>\n<ul>\n<li>high fever </li>\n<li>uncontrolled
        muscle spasms </li>\n<li>stiff muscles </li>\n<li>rapid changes in heart rate
        or blood pressure </li>\n<li>confusion </li>\n<li>loss of consciousness (pass
        out) </li>\n</ul>\n</li>\n<li>\n<span class=\"Bold\">take the antipsychotic
        medicine pimozide (Orap<span class=\"Sup\">&reg;</span>) because taking this
        drug with Lexapro can cause serious heart problems.</span>\n</li>\n</ul>\n<p>\n<span
        class=\"Bold\">What should I tell my healthcare provider before taking Lexapro?
        Ask if you are not sure.</span>\n</p>\n<p>Before starting Lexapro, tell your
        healthcare provider if you: </p>\n<ul>\n<li>Are taking certain drugs such
        as:<ul>\n<li>Triptans used to treat migraine headache </li>\n<li>Medicines
        used to treat mood, anxiety, psychotic or thought disorders, including tricyclics,
        lithium, SSRIs, SNRIs, or antipsychotics </li>\n<li>tramadol </li>\n<li>Over-the-counter
        supplements such as tryptophan or St. John's Wort </li>\n</ul>\n</li>\n<li>have
        liver problems </li>\n<li>have kidney problems </li>\n<li>have heart problems
        </li>\n<li>have or had seizures or convulsions </li>\n<li>have bipolar disorder
        or mania </li>\n<li>have low sodium levels in your blood </li>\n<li>have a
        history of a stroke </li>\n<li>have high blood pressure </li>\n<li>have or
        had bleeding problems </li>\n<li>are pregnant or plan to become pregnant.
        It is not known if Lexapro will harm your unborn baby. Talk to your healthcare
        provider about the benefits and risks of treating depression during pregnancy
        </li>\n<li>are breast-feeding or plan to breast-feed. Some Lexapro may pass
        into your breast milk. Talk to your healthcare provider about the best way
        to feed your baby while taking Lexapro. </li>\n</ul>\n<p>\n<span class=\"Bold\">Tell
        your healthcare provider about all the</span> medicines <span class=\"Bold\">that
        you take,</span> including prescription and non-prescription medicines, vitamins,
        and herbal supplements. Lexapro and some medicines may interact with each
        other, may not work as well, or may cause serious side effects. </p>\n<p>Your
        healthcare provider or pharmacist can tell you if it is safe to take Lexapro
        with your other medicines. Do not start or stop any medicine while taking
        Lexapro without talking to your healthcare provider first. </p>\n<a name=\"nlm34066-1\"></a>\n\n<div
        class=\"Warning\">\n<a name=\"id_9a959585-7ec1-4cb2-853b-ee68b9008d35\"></a><a
        name=\"section-17.1\"></a>\n<p></p>\n<p class=\"First\">If you take Lexapro,
        you should not take any other medicines that contain escitalopram oxalate
        or citalopram hydrobromide including: Celexa. </p>\n</div>\n\n<div class=\"Section\"
        data-sectionCode=\"42229-5\">\n<a name=\"id_e4da10a2-b90a-4e76-8a3a-d0a98a993f0e\"></a><a
        name=\"section-17.1\"></a>\n<p></p>\n<p class=\"First\">\n<span class=\"Bold\">How
        should I take Lexapro?</span>\n</p>\n<ul>\n<li>Take Lexapro exactly as prescribed.
        Your healthcare provider may need to change the dose of Lexapro until it is
        the right dose for you. </li>\n<li>Lexapro may be taken with or without food.
        </li>\n<li>If you miss a dose of Lexapro, take the missed dose as soon as
        you remember. If it is almost time for the next dose, skip the missed dose
        and take your next dose at the regular time. Do not take two doses of Lexapro
        at the same time. </li>\n<li>If you take too much Lexapro, call your healthcare
        provider or poison control center right away, or get emergency treatment.
        </li>\n</ul>\n<p>\n<span class=\"Bold\">What should I avoid while taking Lexapro?</span>\n</p>\n<p>Lexapro
        can cause sleepiness or may affect your ability to make decisions, think clearly,
        or react quickly. You should not drive, operate heavy machinery, or do other
        dangerous activities until you know how Lexapro affects you. Do not drink
        alcohol while using Lexapro. </p>\n<p>What are the possible side effects of
        Lexapro? </p>\n<p>\n<span class=\"Bold\">Lexapro may cause serious side effects,
        including all</span> of those described in the section entitled &ldquo;What
        is the most important information I should know about Lexapro?&rdquo; </p>\n<p>Common
        possible side effects in people who take Lexapro include: </p>\n<ul>\n<li>Nausea
        </li>\n<li>Sleepiness </li>\n<li>Weakness </li>\n<li>Dizziness </li>\n<li>Feeling
        anxious </li>\n<li>Trouble sleeping </li>\n<li>Sexual problems </li>\n<li>Sweating
        </li>\n<li>Shaking </li>\n<li>Not feeling hungry </li>\n<li>Dry mouth </li>\n<li>Constipation
        </li>\n<li>Infection </li>\n<li>Yawning </li>\n</ul>\n<p>Other side effects
        in children and adolescents include: </p>\n<ul>\n<li>increased thirst </li>\n<li>abnormal
        increase in muscle movement or agitation </li>\n<li>nose bleed </li>\n<li>difficult
        urination </li>\n<li>heavy menstrual periods </li>\n<li>possible slowed growth
        rate and weight change. Your child's height and weight should be monitored
        during treatment with Lexapro. </li>\n</ul>\n<p>Tell your healthcare provider
        if you have any side effect that bothers you or that does not go away. These
        are not all the possible side effects of Lexapro. For more information, ask
        your healthcare provider or pharmacist. </p>\n<p>\n<span class=\"Bold\">CALL
        YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS
        TO THE FDA AT 1-800-FDA-1088.</span>\n</p>\n<p>\n<span class=\"Bold\">How
        should I store Lexapro?</span>\n</p>\n<ul>\n<li>Store Lexapro at 25&deg;C
        (77&deg;F); excursions permitted to 15 - 30&deg;C (59-86&deg;F). </li>\n<li>Keep
        Lexapro bottle closed tightly. </li>\n</ul>\n<p>\n<span class=\"Bold\">Keep
        Lexapro and all medicines out of the reach of children.</span>\n</p>\n<p>\n<span
        class=\"Bold\">General information about Lexapro</span>\n</p>\n<p>Medicines
        are sometimes prescribed for purposes other than those listed in a Medication
        Guide. Do not use Lexapro for a condition for which it was not prescribed.
        Do not give Lexapro to other people, even if they have the same condition.
        It may harm them. </p>\n<p>This Medication Guide summarizes the most important
        information about Lexapro. If you would like more information, talk with your
        healthcare provider. You may ask your healthcare provider or pharmacist for
        information about Lexapro that is written for healthcare professionals. </p>\n<p>For
        more information about Lexapro call <span class=\"Bold\">1-800-678-1605</span>
        or go to www.Lexapro.com. </p>\n<p>What are the ingredients in Lexapro? </p>\n<p>\n<span
        class=\"Bold\">Active ingredient: escitalopram oxalate</span>\n</p>\n<p>Inactive
        ingredients: </p>\n<ul>\n<li>\n<span class=\"Bold\">Tablets</span>: talc,
        croscarmellose sodium, microcrystalline cellulose/colloidal silicon dioxide,
        and magnesium stearate. The film coating contains hypromellose, titanium dioxide,
        and polyethylene glycol. </li>\n<li>\n<span class=\"Bold\">Oral Solution:</span>
        sorbitol, purified water, citric acid, sodium citrate, malic acid, glycerin,
        propylene glycol, methylparaben, propylparaben, and natural peppermint flavor.
        </li>\n</ul>\n<p>Forest Pharmaceuticals, Inc.<br>Subsidiary of Forest Laboratories,
        Inc.<br>St. Louis, MO 63045 USA </p>\n<p>Licensed from H. Lundbeck A/S </p>\n<p>Revised&nbsp;May
        2011 </p>\n<p>This Medication Guide has been approved by the U.S. Food and
        Drug Administration. </p>\n</div>\n</div>\n<div class=\"Section\" data-sectionCode=\"51945-4\">\n<a
        name=\"i4i_Principal_display_panel_id_cafd60e7-53c2-4277-9216-3bbd839a8b48\"></a><a
        name=\"section-18\"></a>\n<p></p>\n<h1>\n<a name=\"nlm51945-4\"></a>Principal
        Display Panel - 10 mg</h1>\n<p class=\"First\">Contains Approximately 19200
        tablets</p>\n<p>LEXAPRO<span class=\"Sup\">&reg;</span>\n</p>\n<p>(escitalopram
        oxalate) tablets</p>\n<p>10 mg</p>\n<p>Each tablet equivalent to 10 mg escitalopram</p>\n<p>Rx
        ONLY</p>\n<p>WARNING: Keep out of reach of children.</p>\n<div class=\"Figure\">\n<img
        src=\"image.cfm?id=104317&type=img&name=02194826%2D72a8%2D4436%2D9ade%2De36fa5bb99da%2D02.jpg\"
        alt=\"Lexapro Label\"></div>\n</div>\n<div class=\"Section\" data-sectionCode=\"51945-4\">\n<a
        name=\"i4i_Principal_display_panel_id_45d946bc-f5bb-4b8c-9f18-1003b7e736a1\"></a><a
        name=\"section-19\"></a>\n<p></p>\n<h1>\n<a name=\"nlm51945-4\"></a>Principal
        Display Panel - 10 mg</h1>\n<p class=\"First\">Contains Approximately 6000
        tablets</p>\n<p>LEXAPRO<span class=\"Sup\">&reg;</span>\n</p>\n<p>(escitalopram
        oxalate) tablets</p>\n<p>10 mg</p>\n<p>Each tablet equivalent to 10 mg escitalopram</p>\n<p>Rx
        ONLY</p>\n<p>WARNING: Keep out of reach of children.</p>\n<div class=\"Figure\">\n<img
        src=\"image.cfm?id=104317&type=img&name=02194826%2D72a8%2D4436%2D9ade%2De36fa5bb99da%2D03.jpg\"
        alt=\"Lexapro Label\"></div>\n</div>\n<div class=\"Section\" data-sectionCode=\"51945-4\">\n<a
        name=\"i4i_Principal_display_panel_id_3d72a2bd-09fe-476b-b961-5a4a6fda1c86\"></a><a
        name=\"section-20\"></a>\n<p></p>\n<h1>\n<a name=\"nlm51945-4\"></a>Principal
        Display Panel - 20 mg</h1>\n<p class=\"First\">Contains Approximately 9600
        tablets</p>\n<p>LEXAPRO<span class=\"Sup\">&reg;</span>\n</p>\n<p>(escitalopram
        oxalate) tablets</p>\n<p>20 mg</p>\n<p>Each tablet equivalent to 20 mg escitalopram</p>\n<p>Rx
        ONLY</p>\n<p>WARNING: Keep out of reach of children.</p>\n<div class=\"Figure\">\n<img
        src=\"image.cfm?id=104317&type=img&name=02194826%2D72a8%2D4436%2D9ade%2De36fa5bb99da%2D04.jpg\"
        alt=\"Lexapro Label\"></div>\n</div>\n<div class=\"Section\" data-sectionCode=\"51945-4\">\n<a
        name=\"i4i_Principal_display_panel_id_5c8268d2-ed9a-4cce-8cf0-f7ca9152a781\"></a><a
        name=\"section-21\"></a>\n<p></p>\n<h1>\n<a name=\"nlm51945-4\"></a>Principal
        Display Panel - 20 mg</h1>\n<p class=\"First\">Contains Approximately 4800
        tablets</p>\n<p>LEXAPRO<span class=\"Sup\">&reg;</span>\n</p>\n<p>(escitalopram
        oxalate) tablets</p>\n<p>20 mg</p>\n<p>Each tablet equivalent to 20 mg escitalopram</p>\n<p>Rx
        ONLY</p>\n<p>WARNING: Keep out of reach of children.</p>\n<div class=\"Figure\">\n<img
        src=\"image.cfm?id=104317&type=img&name=02194826%2D72a8%2D4436%2D9ade%2De36fa5bb99da%2D05.jpg\"
        alt=\"Lexapro Label\"></div>\n</div>\n<div class=\"Section\" data-sectionCode=\"51945-4\">\n<a
        name=\"i4i_Principal_display_panel_id_02a97d68-4f94-4d62-87b8-7606f9490937\"></a><a
        name=\"section-22\"></a>\n<p></p>\n<h1>\n<a name=\"nlm51945-4\"></a>Principal
        Display Panel - 20 mg</h1>\n<p class=\"First\">Contains Approximately 2400
        tablets</p>\n<p>LEXAPRO<span class=\"Sup\">&reg;</span>\n</p>\n<p>(escitalopram
        oxalate) tablets</p>\n<p>20 mg</p>\n<p>Each tablet equivalent to 20 mg escitalopram</p>\n<p>Rx
        ONLY</p>\n<p>WARNING: Keep out of reach of children.</p>\n<div class=\"Figure\">\n<img
        src=\"image.cfm?id=104317&type=img&name=02194826%2D72a8%2D4436%2D9ade%2De36fa5bb99da%2D06.jpg\"
        alt=\"Lexapro Label\"></div>\n</div>\n</div>\n<div class=\"DataElementsTables\">\n<table
        width=\"100%\" cellPadding=\"3\" cellSpacing=\"0\" class=\"contentTablePetite\">\n<tbody>\n<tr>\n<td
        class=\"contentTableTitle\"><strong>LEXAPRO&nbsp;\t\t\n\t\t\t\t\t</strong>\n<br>\n<span
        class=\"contentTableReg\">escitalopram oxalate tablet</span></td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"5\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"4\">Product Information</td>\n</tr>\n<tr
        class=\"formTableRowAlt\">\n<td class=\"formLabel\">Product Type</td><td class=\"formItem\">HUMAN
        PRESCRIPTION DRUG LABEL</td><td class=\"formLabel\">Item Code (Source)</td><td
        class=\"formItem\">NDC:55154-4619(NDC:0456-2010)</td>\n</tr>\n<tr class=\"formTableRow\">\n<td
        class=\"formLabel\" width=\"30%\">Route of Administration</td><td class=\"formItem\">ORAL</td><td
        class=\"formLabel\" width=\"30%\">DEA Schedule</td><td class=\"formItem\">&nbsp;&nbsp;&nbsp;&nbsp;\n\t\t\t\t\t\t\t</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"3\">Active Ingredient/Active Moiety</td>\n</tr>\n<tr>\n<td
        class=\"formTitle\">Ingredient Name</td><td class=\"formTitle\">Basis of Strength</td><td
        class=\"formTitle\">Strength</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>ESCITALOPRAM OXALATE</strong> (ESCITALOPRAM) </td><td
        class=\"formItem\">ESCITALOPRAM</td><td class=\"formItem\">10&nbsp;mg</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"2\">Inactive Ingredients</td>\n</tr>\n<tr>\n<td
        class=\"formTitle\">Ingredient Name</td><td class=\"formTitle\">Strength</td>\n</tr>\n<tr
        class=\"formTableRowAlt\">\n<td class=\"formItem\"><strong>talc</strong></td><td
        class=\"formItem\">&nbsp;</td>\n</tr>\n<tr class=\"formTableRow\">\n<td class=\"formItem\"><strong>croscarmellose
        sodium</strong></td><td class=\"formItem\">&nbsp;</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td><td class=\"formItem\">&nbsp;</td>\n</tr>\n<tr
        class=\"formTableRow\">\n<td class=\"formItem\"><strong>silicon dioxide</strong></td><td
        class=\"formItem\">&nbsp;</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>magnesium stearate</strong></td><td class=\"formItem\">&nbsp;</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"4\">Product Characteristics</td>\n</tr>\n<tr
        class=\"formTableRowAlt\">\n<td class=\"formLabel\">Color</td><td class=\"formItem\">white
        (White) </td><td class=\"formLabel\">Score</td><td class=\"formItem\">2 pieces</td>\n</tr>\n<tr
        class=\"formTableRow\">\n<td class=\"formLabel\">Shape</td><td class=\"formItem\">ROUND
        (Round) </td><td class=\"formLabel\">Size</td><td class=\"formItem\">7mm</td>\n</tr>\n<tr
        class=\"formTableRowAlt\">\n<td class=\"formLabel\">Flavor</td><td class=\"formItem\"></td><td
        class=\"formLabel\">Imprint Code</td><td class=\"formItem\">\n                           \n
        \                          F;L;10\n                        </td>\n</tr>\n<tr
        class=\"formTableRow\">\n<td class=\"formLabel\">Contains</td><td class=\"formItem\">&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"4\">Packaging</td>\n</tr>\n<tr>\n<td
        class=\"formTitle\" width=\"1\">#</td><td class=\"formTitle\">Item Code</td><td
        class=\"formTitle\">Package Description</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>1</strong></td><td class=\"formItem\">NDC:55154-4619-8</td><td
        class=\"formItem\">19200  in 1 BOTTLE, PLASTIC</td>\n</tr>\n<tr class=\"formTableRow\">\n<td
        class=\"formItem\"><strong>2</strong></td><td class=\"formItem\">NDC:55154-4619-2</td><td
        class=\"formItem\">6000  in 1 BOTTLE, PLASTIC</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td></td>\n</tr>\n<tr>\n<td
        class=\"normalizer\">\n<table class=\"formTableMorePetite\" cellspacing=\"0\"
        cellpadding=\"3\" width=\"100%\">\n<tr>\n<td class=\"formHeadingReg\" colspan=\"4\"><span
        class=\"formHeadingTitle\">Marketing Information</span></td>\n</tr>\n<tr>\n<td
        class=\"formTitle\">Marketing Category</td><td class=\"formTitle\">Application
        Number or Monograph Citation</td><td class=\"formTitle\">Marketing Start Date</td><td
        class=\"formTitle\">Marketing End Date</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\">NDA</td><td class=\"formItem\">NDA021323</td><td class=\"formItem\">08/14/2002</td><td
        class=\"formItem\"></td>\n</tr>\n</table>\n</td>\n</tr>\n</tbody>\n</table>\n<table
        width=\"100%\" cellPadding=\"3\" cellSpacing=\"0\" class=\"contentTablePetite\">\n<tbody>\n<tr>\n<td
        class=\"contentTableTitle\"><strong>LEXAPRO&nbsp;\t\t\n\t\t\t\t\t</strong>\n<br>\n<span
        class=\"contentTableReg\">escitalopram oxalate tablet</span></td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"5\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"4\">Product Information</td>\n</tr>\n<tr
        class=\"formTableRowAlt\">\n<td class=\"formLabel\">Product Type</td><td class=\"formItem\">HUMAN
        PRESCRIPTION DRUG LABEL</td><td class=\"formLabel\">Item Code (Source)</td><td
        class=\"formItem\">NDC:55154-4620(NDC:0456-2020)</td>\n</tr>\n<tr class=\"formTableRow\">\n<td
        class=\"formLabel\" width=\"30%\">Route of Administration</td><td class=\"formItem\">ORAL</td><td
        class=\"formLabel\" width=\"30%\">DEA Schedule</td><td class=\"formItem\">&nbsp;&nbsp;&nbsp;&nbsp;\n\t\t\t\t\t\t\t</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"3\">Active Ingredient/Active Moiety</td>\n</tr>\n<tr>\n<td
        class=\"formTitle\">Ingredient Name</td><td class=\"formTitle\">Basis of Strength</td><td
        class=\"formTitle\">Strength</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>ESCITALOPRAM OXALATE</strong> (ESCITALOPRAM) </td><td
        class=\"formItem\">ESCITALOPRAM</td><td class=\"formItem\">20&nbsp;mg</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"2\">Inactive Ingredients</td>\n</tr>\n<tr>\n<td
        class=\"formTitle\">Ingredient Name</td><td class=\"formTitle\">Strength</td>\n</tr>\n<tr
        class=\"formTableRowAlt\">\n<td class=\"formItem\"><strong>talc</strong></td><td
        class=\"formItem\">&nbsp;</td>\n</tr>\n<tr class=\"formTableRow\">\n<td class=\"formItem\"><strong>croscarmellose
        sodium</strong></td><td class=\"formItem\">&nbsp;</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td><td class=\"formItem\">&nbsp;</td>\n</tr>\n<tr
        class=\"formTableRow\">\n<td class=\"formItem\"><strong>silicon dioxide</strong></td><td
        class=\"formItem\">&nbsp;</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>magnesium stearate</strong></td><td class=\"formItem\">&nbsp;</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"4\">Product Characteristics</td>\n</tr>\n<tr
        class=\"formTableRowAlt\">\n<td class=\"formLabel\">Color</td><td class=\"formItem\">white
        (White) </td><td class=\"formLabel\">Score</td><td class=\"formItem\">2 pieces</td>\n</tr>\n<tr
        class=\"formTableRow\">\n<td class=\"formLabel\">Shape</td><td class=\"formItem\">ROUND
        (Round) </td><td class=\"formLabel\">Size</td><td class=\"formItem\">10mm</td>\n</tr>\n<tr
        class=\"formTableRowAlt\">\n<td class=\"formLabel\">Flavor</td><td class=\"formItem\"></td><td
        class=\"formLabel\">Imprint Code</td><td class=\"formItem\">\n                           \n
        \                          F;L;20\n                        </td>\n</tr>\n<tr
        class=\"formTableRow\">\n<td class=\"formLabel\">Contains</td><td class=\"formItem\">&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td>\n<table
        class=\"formTablePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingTitle\" colspan=\"4\">Packaging</td>\n</tr>\n<tr>\n<td
        class=\"formTitle\" width=\"1\">#</td><td class=\"formTitle\">Item Code</td><td
        class=\"formTitle\">Package Description</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>1</strong></td><td class=\"formItem\">NDC:55154-4620-8</td><td
        class=\"formItem\">9600  in 1 BOTTLE, PLASTIC</td>\n</tr>\n<tr class=\"formTableRow\">\n<td
        class=\"formItem\"><strong>2</strong></td><td class=\"formItem\">NDC:55154-4620-2</td><td
        class=\"formItem\">4800  in 1 BOTTLE, PLASTIC</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\"><strong>3</strong></td><td class=\"formItem\">NDC:55154-4620-9</td><td
        class=\"formItem\">2400  in 1 BOTTLE, PLASTIC</td>\n</tr>\n</table>\n</td>\n</tr>\n<tr>\n<td></td>\n</tr>\n<tr>\n<td
        class=\"normalizer\">\n<table class=\"formTableMorePetite\" cellspacing=\"0\"
        cellpadding=\"3\" width=\"100%\">\n<tr>\n<td class=\"formHeadingReg\" colspan=\"4\"><span
        class=\"formHeadingTitle\">Marketing Information</span></td>\n</tr>\n<tr>\n<td
        class=\"formTitle\">Marketing Category</td><td class=\"formTitle\">Application
        Number or Monograph Citation</td><td class=\"formTitle\">Marketing Start Date</td><td
        class=\"formTitle\">Marketing End Date</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\">NDA</td><td class=\"formItem\">NDA021323</td><td class=\"formItem\">08/14/2002</td><td
        class=\"formItem\"></td>\n</tr>\n</table>\n</td>\n</tr>\n</tbody>\n</table>\n<table
        class=\"formTableMorePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingReg\" colspan=\"4\"><span class=\"formHeadingTitle\">Labeler
        -&nbsp;</span>Cardinal Health\n\t\t\t\t\t\t\t(188557102)\n\t\t\t\t\t\t</td>\n</tr>\n</table>\n<table
        class=\"formTableMorePetite\" cellspacing=\"0\" cellpadding=\"3\" width=\"100%\">\n<tr>\n<td
        class=\"formHeadingReg\" colspan=\"4\"><span class=\"formHeadingTitle\">Establishment</span></td>\n</tr>\n<tr>\n<td
        class=\"formTitle\">Name</td><td class=\"formTitle\">Address</td><td class=\"formTitle\">ID/FEI</td><td
        class=\"formTitle\">Business Operations</td>\n</tr>\n<tr class=\"formTableRowAlt\">\n<td
        class=\"formItem\">Cardinal Health</td><td class=\"formItem\"></td><td class=\"formItem\">188557102</td><td
        class=\"formItem\">REPACK(55154-4619, 55154-4620)</td>\n</tr>\n</table>\n</div>\n<p>\n<div
        class=\"EffectiveDate\">Revised: 08/2013<div class=\"DocumentMetadata\">\n<div>Document
        Id: 02194826-72a8-4436-9ade-e36fa5bb99da</div>\n<div>Set id: b49f45d7-432f-4529-b382-3a65f7643e2d</div>\n<div>Version:
        2</div>\n<div>Effective Time: 20130813</div>\n</div>\n</div>&nbsp;<div class=\"DistributorName\">Cardinal
        Health</div>\n</p>\n\r\n</div>\r\n</div>\r\n\r\n\r\n<div id=\"nlmfooter\">\r\n\t<a
        href=\"http://www.nlm.nih.gov\">\r\n\t\t<img  src=\"/dailymed/images/logo.gif\"\r\n\t\talt=\"Visit
        The National Library of Medicine\" />\r\n\t</a>\r\n\t<a href=\"http://www.nlm.nih.gov/copyright.html\">Copyright</a>,\r\n\t<a
        href=\"http://www.nlm.nih.gov/privacy.html\">Privacy</a>,\r\n\t<a href=\"http://www.nlm.nih.gov/accessibility.html\">Accessibility</a><br
        />\r\n\t<a href=\"http://www.nlm.nih.gov\">U.S. National Library of Medicine</a>,
        8600 Rockville Pike, Bethesda, MD 20894<br />\r\n\t<a href=\"http://www.nih.gov/\">National
        Institutes of Health</a>,\r\n\t<a href=\"http://www.hhs.gov/\">Health &amp;
        Human Services</a>\r\n</div>\r\n\r\n\r\n</body>\r\n</html>\r\n"
    http_version: 
  recorded_at: Fri, 06 Sep 2013 19:30:57 GMT
recorded_with: VCR 2.5.0
